

LOOKS HEALTH SERVICES LIMITED

14TH ANNUAL REPORT

F.Y. 2024-2025

SR. NO.	PARTICULARS	PAGE NO.
1.	Corporate Information	3
2.	Notice	5
3.	Board's Report	14
4.	Annexure 1 to Boards Report : Management Discussion & Analysis Report	23
5.	Annexure 2 to Boards Report : Corporate Governance Report	26
6.	Annexure 3 to Boards Report : Secretarial Audit Report	41
7.	Annexure 4 to Boards Report : Remuneration Policy For Directors, KMPs And Other Employees	44
8.	Annexure 5 to Boards Report : Directors' Employees Remuneration	45
9.	Annexure 6 to Boards Report : CFO/MD Certification	46
10.	Annexure 7 to Boards Report : Declaration on Code of Conduct	47
11.	Annexure 8 to Boards Report : Certificate Regarding Compliance With The Conditions Of Corporate Governance	48
12.	Independent Auditor's Report & Financial Statements	49

CORPORATE INFORMATION

BOARD OF DIRECTORS

1.	Mr. Pritesh Champalal Doshi	Managing Director cum Chairman	Resign as Chairman w.e.f. 05.09.2024
2.	Ms. Sejal Hitesh Jain	Non-Executive Independent Director	
3.	Mr. Krishna Mukesh Sangani	Non-Executive Independent Director	Resign w.e.f. 30.09.2024
4.	Ms. Monika Joshi	Whole Time Director cum Chairman	Appoint w.e.f. 05.09.2024 Regularize w.e.f. 30.09.2024
5.	Mr. Mihir Ganappa	Non-Executive Director	Appoint w.e.f. 05.09.2024 Regularize w.e.f. 30.09.2024
6.	Mr. Dhruv Pravinbhai Rajgor	Non-Executive Independent Director	Appoint w.e.f. 05.09.2024 Regularize w.e.f. 30.09.2024
7.	Mr. Bhavin Mahendrakumar Hirpara	Non-Executive Independent Director	Appoint w.e.f. 05.09.2024 Regularize w.e.f. 30.09.2024
8.	Mr. Milinath Gavas	Chief Financial Officer	

COMPANY SECRETARY & COMPLIANCE OFFICER

1. Ms. Kanchan Kaku resign w.e.f. 17.02.2025

INTERNAL AUDITOR

1. Dhruvaprakash & Co.
B-408, Naman Midtown, Senapati Bapat Marg, Elphinstone Road (West) Mumbai - 400013.
Tel: 022-2438 2100, Email: cadpshetty@gmail.com

SECRETARIAL AUDITOR

1. VKM & Associates
116, Trinity Bldg, 1st Floor, 227, Dr. C H Street, Behind Parsi Dairy, Marine Lines (E), Mumbai -400002.
Tel: 022-22077267, Email: vkmassociates@yahoo.com

STATUTORY AUDITORS

1. **Parekh Shah & Lodha**
Chartered Accountants (resigns w.e.f. 14.08.2024)
BKC Centre, 31-E, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai – 400053
Tel No- 022-30706021/44, Email: pslca1988@gmail.com
2. **M/s. KPSJ & ASSOCIATES LLP**
Chartered Accountants (Appoint to fill casual vacancy w.e.f. 05.09.2024 and take approval of members in 13th AGM)
B-1002, Mondeal Square, Nr. Prahladnagar Garden, S.G. Highway, Ahmedabad- 380015, Gujarat, India
Tel. + 91 079 66653333/66653301/02/03 MOBILE NO.: +91 7698833000 E-mail: info@kpsjca.com

PRINCIPAL BANKER

YES BANK LTD.

842, Yes Bank Ltd, Naroda Ahmedabad Branch, Krishna Arcade Shop No 5, Lot No Cm10 near Telephone Exchange, G I D C Naroda, Ahmedabad-382330, IFSC : Yesb0000842, MICR: 380532021

REGISTERED OFFICE

5 & 9, Floor-1 & 2, Plot-27/33, Beaumon Chambers, Nagindas Master Lane, Hutatma Chowk, Fort, Mumbai City, Mumbai, Maharashtra, India, 400001 upto 28th November, 2024
35, Floor-2, Plot-3/5, Seth Lalji Dayal Building, Dadi Seth Agiary Lane, Malharrao wadi, Kalbadevi, Mumbai-400002, Maharashtra, India w.e.f. 28th November, 2024
Email: compliancelhsl@gmail.com
Website: <https://looksclinic.in/>

BOOK CLOSURE

Date: 19.09.2025 to 30.09.2025 (both days inclusive)

REGISTRARS AND TRANSFER AGENTS

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

A/505 Dattani Plaza, Andheri Kurla Road, Safeed Pool, Andheri (East), Mumbai - 400072

Tel: 022-49721245, 022-28511022 Email: admin@skylinerta.com & pravin.cm@skylinerta.com

AUDIT COMMITTEE

Ms. Sejal Jain- Non-Executive Independent Director- Chairperson

Mr. Pritesh Doshi - Managing Director-Member

Mr. Krishna Sangani - Non-Executive Independent Director-Member

Re-constitute committee w.e.f. 01.10.2024 as under

Mr. Dhruv Pravinbhai Rajgor- Non - Executive Independent Director– Chairperson

Mr. Bhavin Mahendrakumar Hirpara- Non-Executive Independent Director– Member

Ms. Monika Joshi – Whole Time Director – Member

NOMINATION & REMUNERATION COMMITTEE

Ms. Sejal Jain- Non-Executive Independent Director- Chairperson

Mr. Pritesh Doshi - Managing Director-Member

Mr. Krishna Sangani - Non-Executive Independent Director-Member

Re-constitute committee w.e.f. 01.10.2024 as under

Mr. Dhruv Pravinbhai Rajgor- Non - Executive Independent Director– Chairperson

Mr. Bhavin Mahendrakumar Hirpara- Non-Executive Independent Director– Member

Mr. Mihir Ganappa– Non Executive Director – Member

STAKEHOLDER RELATIONSHIP COMMITTEE

Ms. Sejal Jain- Non-Executive Independent Director- Chairperson

Mr. Pritesh Doshi - Managing Director-Member

Mr. Krishna Sangani - Non-Executive Independent Director-Member

Re-constitute committee w.e.f. 01.10.2024 as under

Mr. Dhruv Pravinbhai Rajgor- Non - Executive Independent Director– Chairperson

Mr. Bhavin Mahendrakumar Hirpara- Non-Executive Independent Director– Member

Ms. Monika Joshi – Whole Time Director – Member

14TH ANNUAL GENERAL MEETING

Date: 30th September, 2025

Time: 11:00 A.M.

Place: Through VC/OAVM

NOTICE IS HEREBY GIVEN THAT 14TH ANNUAL GENERAL MEETING OF THE MEMBERS OF THE COMPANY WILL BE HELD ON TUESDAY, 30TH SEPTEMBER, 2025 AT 11:00 A.M. THROUGH VC/OAVM TO TRANSACT THE FOLLOWING BUSINESS

ORDINARY BUSINESS:

1. TO CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENT OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025 AND THE REPORTS OF THE BOARD OF DIRECTORS AND AUDITORS THEREON AND, IN THIS REGARD, TO CONSIDER AND IF THOUGHT FIT, TO PASS, WITH OR WITHOUT MODIFICATION(S), THE FOLLOWING RESOLUTIONS AS AN ORDINARY RESOLUTIONS:

“RESOLVED THAT the audited standalone financial statement of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors and Auditors thereon, as circulated to the Members, be and are hereby considered and adopted.”

2. TO APPOINT A DIRECTOR IN PLACE OF MS. MONIKA JOSHI (DIN: 10652494), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HERSELF FOR RE-APPOINTMENT AND, IN THIS REGARD, TO CONSIDER AND IF THOUGHT FIT, TO PASS THE FOLLOWING RESOLUTION AS AN ORDINARY RESOLUTION:

“RESOLVED THAT pursuant to Section 152 and other applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification(s) and/or re-enactment(s) thereof, for the time being in force) read with the Articles of Association of the Company, Ms. Monika Joshi (DIN: 10652494), who retires by rotation at this ensuing Annual General Meeting of the Company, and being eligible, seeks re-appointment, be and is hereby re-appointed as a Executive Director of the Company, liable to retire by rotation, on such remuneration as may be recommended by the Board of Directors from time to time which shall be within the maximum limits as approved by the shareholders of the Company.”

SPECIAL BUSINESS

3. TO APPOINT MS. SHUBHANGI AGARWAL, A PRACTICING COMPANY SECRETARY (ACS NO.: 63219; CP NO.: 23802 & PEER REVIEW CERTIFICATE NO.: 2728/2022), AS THE SECRETARIAL AUDITOR OF THE COMPANY AND, IN THIS REGARD, TO CONSIDER AND IF THOUGHT FIT, TO PASS THE FOLLOWING RESOLUTION AS AN ORDINARY RESOLUTION:

“RESOLVED THAT pursuant to Section 204 and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), and based on the recommendation of the Audit Committee and the Board of Directors of the Company, Ms. Shubhangi Agarwal, A Practicing Company Secretary (ACS NO.: 63219; CP NO.: 23802 & Peer Review Certificate No.: 2728/2022), be and is hereby appointed as the Secretarial Auditor of the Company, for a term of five consecutive years from financial year 2025-26 to financial year 2029-30, on such annual remuneration plus applicable taxes and reimbursement of out-of-pocket expenses as shall be fixed by the Board of Directors of the Company in consultation with the Secretarial Auditor.”

“RESOLVED FURTHER THAT the Board of Directors and/or the Company Secretary of the Company, be and are hereby authorised to settle any question, difficulty, or doubt, that may arise in giving effect to this resolution and to do all such acts, deeds, and things as may be necessary, expedient, and desirable for the purpose of giving effect to this resolution and for matters concerned or incidental thereto.”

4. RE-DESIGNATION AND APPOINTMENT OF MR. PRITESH CHAMPALAL DOSHI (DIN: 05155318) AS “WHOLE TIME DIRECTOR” (ALSO A “WHOLE-TIME KEY MANAGERIAL PERSONNEL”) OF THE COMPANY

To consider and, if thought fit, to pass the following Resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013 (hereinafter referred to as the “Act”) and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] and the applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and relevant provisions of the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and Audit Committee and in accordance with the approval of the Board and subject to such other requisite consents, permissions and approvals, as may be required, Mr. Pritesh Champalal Doshi (DIN: 05155318) be and is hereby re-designated and appointed as “Whole Time Director” (also, a “Whole-time Key Managerial Personnel”) of the Company with effect from September 30, 2025 till the end of her current tenure upto March 31, 2026 and that the other terms and conditions of her appointment including remuneration as approved at the 10th AGM of the company held on September 30, 2021 shall remain unchanged.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds, matters, things etc. and take all such steps as may be necessary proper expedient or incidental for the purpose of giving effect to the resolution.”

5. RE-DESIGNATION AND APPOINTMENT OF MS. MONIKA JOSHI (DIN: 10652494) AS “MANAGING DIRECTOR” (ALSO A “WHOLE-TIME KEY MANAGERIAL PERSONNEL”) OF THE COMPANY

To consider and, if thought fit, to pass the following Resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule V and all other applicable provisions, if any, of the Companies Act, 2013 (hereinafter referred to as the “Act”) and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] and the applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and relevant provisions of the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and Audit Committee and in accordance with the approval of the Board and subject to such other requisite consents, permissions and approvals, as may be required, Ms. Monika Joshi (DIN: 10652494) be and is hereby re-designated and appointed as “Managing Director” (also, a “Whole-time Key Managerial Personnel”) of the Company with effect from September 30, 2025 till the end of her current tenure upto September 04, 2029 and that the other terms and conditions of her appointment including remuneration as approved at the 13th AGM of the company held on September 30, 2024 shall remain unchanged.”

“RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds, matters, things etc. and take all such steps as may be necessary proper expedient or incidental for the purpose of giving effect to the resolution.”

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN: 10652494**

**DATE: 04.09.2025
PLACE: MUMBAI**

Details of the Directors seeking re-appointment at the 14TH Annual General Meeting of the company as per Regulation 36(3) SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015

Name of Director	Ms. Monika Joshi
DIN	10652494
Date of Birth / Age	20/06/1988
Nationality	Indian
Qualifications	B Com
Expertise in specific functional areas	Expertise: Business Leadership & Finance
Terms and conditions of appointment or re-appointment along with details of remuneration sought to be paid	Executive Director , liable to retire by rotation
The remuneration last drawn	Nil
Date of first appointment on the Board	September 05, 2024 as Executive Director and designated with effect from September 05, 2024 as Whole Time Director of the Company
Shareholding in the company	Ms Monika Joshi does not hold by herself or for any other person on a beneficial basis, any shares in the Company.
Relationship with other Directors, Manager and other Key Managerial Personnel of the company	There is no inter-se relationship between Ms Monika Joshi and other members of the Board and Key Managerial Personnel of the Company.
The number of Meetings of the Board attended during the year	Total 10 Meeting Held During The F.Y. 2024-25 Out of the 7 Meeting Board Meeting Held During Tenure Of Director Out Of Which 7 Meeting Attended By Her.
Other Directorships, Membership / Chairmanship of Committees of other Boards	Directorship: Nil
	Chairperson of Committees: Nil
	Member of Committees: Nil

NOTES:

1. The Government of India, Ministry of Corporate Affairs has allowed conducting Annual General Meeting through Video Conferencing (VC) or Other Audio Visual Means (OAVM) and dispensed the personal presence of the members at the meeting. Accordingly, the Ministry of Corporate Affairs issued General Circulars No. 14/2020 dated April 8, 2020; No. 17/2020 dated April 13, 2020, No. 20/2020 dated May 5, 2020; No. 22/2020 dated June 15, 2020; No. 33/2020 dated September 28, 2020; No. 39/2020 dated December 31, 2020; No. 10/2021 dated June 23, 2021; No. 20/2021 dated December 8, 2021; No. 21/2021 dated December 14, 2021; No. 2/2022 dated May 5, 2022; No. 10/2022 dated December 28, 2022; No. 9/2023 dated September 25, 2023; and No. 9/2024 dated September 19, 2024 ("MCA Circulars") and Circular No. SEBU/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, Circular No. SEBI/HO/DDHS/P/CIR/2022/0063 dated May 13, 2022, SEBI/HO/CRD/ POD-2/P/CIR/2023/4 dated January 5, 2023, Circular No. SEBU/HO/CFD/CFD-POD-2/P/CIR/2023/167 dated October 7, 2023 and Circular No. SEBI/HO/CFD/ CFD-POD-2/P/CIR/2024/133 dated October 3, 2024 issued by the Securities Exchange Board of India ("SEBI Circulars") prescribing the procedures and manner of conducting the Annual General Meeting through VC/ OAVM. In terms of the said circulars, the 14TH Annual General Meeting (AGM) of the Members will be held through VC/OAVM. Hence, Members can attend and participate in the 14TH AGM through VC/OAVM only. The detailed procedure for participation in the meeting through VC/OAVM is as per note no. 19 and available at the Company's website: <https://looksclinic.in/>.

2. The helpline number regarding any query/ assistance for participation in the 14TH AGM through VC/OAVM is Toll Free: 1800 22 55 33.

3. Information regarding appointment/re-appointment of Directors and Explanatory Statement in respect of special businesses to be transacted pursuant to Section 102 of the Companies Act, 2013 ("Act") and/or Regulation 36(3) of the (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), is annexed hereto.

4. Pursuant to the Circular No. 14/2020 dated April 8, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this 14TH AGM. However, the Body Corporate are entitled to appoint authorised representatives for attending the 14TH AGM through VC/OAVM, participating thereat and casting their votes through e-voting.

5. The attendance of the Members attending the 14TH AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.

6. In line with the aforesaid MCA Circulars, the Notice calling the 14TH AGM has been uploaded on the website of the Company at <https://looksclinic.in/>. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com. The said Notice of the 14TH AGM is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

7. Shareholders seeking any information with regard to accounts are requested to write to the Company at least 10 days before the meeting so as to enable the management to keep the information ready.

8. Shareholders holding the shares in physical mode are requested to notify immediately the change of their address and bank particulars to the R & T Agent of the Company. In case shares held in dematerialized form, the information regarding change of address and bank particulars should be given to their respective Depository Participant.

9. In terms of Section 72 of the Act, nomination facility is available to individual members holding shares in the physical form. The members, who are desirous of availing this facility, may kindly write to Company's R & T Agent for nomination form by quoting their folio number.

10. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Act and all other documents referred to in the Notice will be available for inspection in electronic mode.

11. The Shareholders can join the 14TH AGM in the VC/ OAVM mode 15 (fifteen) minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the 14TH AGM through VC/OAVM will be made available for 1,000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the 14TH AGM without restriction on account of first come first served basis.

12. Process and manner for Shareholders opting for voting through electronic means:

- Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI Listing Regulations (as amended), and pursuant to the MCA Circulars, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the 14TH AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL), as the authorised e-voting agency for facilitating voting through electronic means. The facility of casting votes by a member using remote e-voting as well as e-voting system on the date of the 14TH AGM will be provided by NSDL.
- Shareholders whose names are recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the **Cut-off date** i.e. Friday, September 26, 2025 shall be entitled to avail the facility of remote e-

voting as well as venue voting system on the date of the 14TH AGM. Any recipient of the Notice, who has no voting rights as on the Cut-off date, shall treat this Notice as intimation only.

- A person who has acquired the shares and has become a member of the Company after the dispatch of the Notice of the 14TH AGM and prior to the **Cut-off date i.e.** Friday, September 26, 2025 shall be entitled to exercise his/her vote either electronically i.e. remote e-voting or venue voting system on the date of the 14TH AGM by following the procedure mentioned in this part.
- The remote e-voting will commence on Saturday, September 27, 2025 at 9.00 a.m. and will end on Monday, September 29, 2025 at 5.00 p.m. During this period, the members of the Company holding shares either in physical form or in demat form as on the Cut-off date i.e. Friday, September 26, 2025 may cast their vote electronically. The members will not be able to cast their vote electronically beyond the date and time mentioned above and the remote e-voting module shall be disabled for voting by NSDL thereafter.
- Once the vote on a resolution is cast by the member, he/she shall not be allowed to change it subsequently or cast the vote again.
- The voting rights of the members shall be in proportion to their share in the paid up equity share capital of the Company as on the Cut-off date i.e. Friday, September 26, 2025.
- The Company has appointed CS Shubhangi Agarwal, Practicing Company Secretary (Membership No. ACS: 63219; CP No: 23802), to act as the Scrutinizer for conducting the remote e-voting process as well as the venue voting system on the date of the 14TH AGM, in a fair and transparent manner.

13. Process for those Shareholders whose email ids are not registered:

- For Physical shareholders- Please provide necessary details like folio no., name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to RTA email id pravin.cm@skylinerta.com / admin@skylinerta.com.
- For Demat shareholders - Please update your e-mail id and mobile no. with your respective Depository Participant (DP).
- For Individual Demat Shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

14. The instructions for Shareholders for remote e-voting and joining AGM are as under:

The remote e-voting period begins on Saturday, September 27, 2025 at 9.00 a.m. and will end on Monday, September 29, 2025 at 5.00 p.m. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members/Beneficial Owners as on the record date (cut-off date) i.e. Friday, September 26, 2025 may cast their vote electronically? The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Friday, September 26, 2025.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility. Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	- Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. - If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp - Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. - Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by

	scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on  App Store  Google Play  
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website http://www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in http://www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request mailto:evoting@nsdl.co.in or call at: 022 - 4886 7000 and 022 - 2499 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at mailto:helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: [https:// www.evoting.nsdl.com/](https://www.evoting.nsdl.com/) either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen. Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at [https:// eservices.nsdl.com/](https://eservices.nsdl.com/) with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
---	-------------------------

a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***.

5. Password details for shareholders other than Individual shareholders are given below:

- If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
- How to retrieve your 'initial password'?
 - If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

- Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
- Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
- If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
- Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join AGM on NSDL e-Voting system.

How to cast your vote electronically and join AGM on NSDL e-Voting system?

- After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and who's voting cycle and General Meeting is in active status.
- Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/ OAVM" link placed under "Join Meeting".
- Now you are ready for e-Voting as the Voting page opens.
- Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
- Upon confirmation, the message "Vote cast successfully" will be displayed.
- You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for Shareholders:

- Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorised signatory(ies) who are authorised to vote, to the Scrutinizer by e-mail to ravi@ravics.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution/Power of Attorney/Authority Letter etc. by clicking on "Upload Board Resolution/ Authority Letter" displayed under "e-Voting" tab in their login.
- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on: 022 - 4886 7000 or send a request to Ms Pallavi Mhatre at evoting@nsdl.com.

17. Process for those Shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to lookshealthserv@gmail.com.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to lookshealthserv@gmail.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

18. The instructions for Shareholders for e-voting on the day of the AGM are as under:

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

19. The instructions for Shareholders for attending the AGM through VC/OAVM are as under:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM" placed under "Join meeting" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/ Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. For ease of conduct, Members who would like to ask questions may send their questions in advance at least (7) days before AGM mentioning their name, demat account number/folio number, email id, mobile number to lookshealthserv@gmail.com and register themselves as a speaker. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM.
6. Since the AGM will be held through VC/OAVM, the Route Map is not annexed in this Notice.

20. The Scrutinizer shall, after the conclusion of voting at the 14TH AGM, unblock the votes cast through remote e-Voting and count the same, and count the votes cast during the 14TH AGM, and shall make, not later than 48 hours from the conclusion of the 14TH AGM, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same and declare the result of the voting forthwith. The Scrutinizer's decision on the validity of the votes shall be final. The results declared along with the Scrutinizer's Report shall be placed on the Company's website <https://looksclinic.in/> within forty-eight hours of the passing of the Resolutions at the 14TH Annual General Meeting of the Company and shall also be communicated to the Stock Exchanges where the shares of the Company are listed.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN: 10652494**

**DATE: 04.09.2025
PLACE: MUMBAI**

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

ITEM NO 3

Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 ("SEBI Listing Regulations"), on the basis of recommendation of Board of Directors, the Company shall appoint or re-appoint an individual as Secretarial Auditor for not more than one term of five consecutive years; or a Secretarial Audit firm as Secretarial Auditor for not more than two terms of five consecutive years, with the approval of the shareholders in Annual General Meeting ("AGM").

Based on the recommendation of the Audit Committee, the Board of Directors has approved the appointment of Ms. Shubhangi Agarwal, Company Secretaries in Practice (ACS NO.: 63219; CP NO.: 23802 & Peer Review Certificate No.: 2728/2022), as the Secretarial Auditors of the Company for a period of five consecutive financial years from 2025-26 to 2029-30. The appointment is subject to shareholders' approval at the AGM. While recommending Ms. Shubhangi Agarwal for appointment, the Audit Committee and the Board based on past audit experience of the auditor particularly in auditing large companies, valued various factors, including the auditor capability to handle a diverse and complex business environment, its existing experience in the various business segments, the clientele it serves, and its technical expertise.

Pursuant to Regulation 36(5) of SEBI Listing Regulations as amended, the credentials and terms of appointment of Ms. Shubhangi Agarwal are as under:

Profile:

Ms. Shubhangi Agarwal possesses around 4 years of experience in the fields of Accounts, Audit and handling compliances under various Corporate Laws, listing agreement; Rights Issues, Bonus Issues, Preferential Allotments, Due Diligence, Incorporation, Drafting of agreements, Appearance before Quasi-Judicial Authority, Conversion, Buyback, Trademark, Bank Audit etc. She is also associated with corporate groups Like Basant group of Companies, Jindal group of Companies, Mudra group of companies, Nagrik cooperative Bank and is also a member in board of Sadbhav Consumers Multistate Cooperative society.

Terms of appointment:

Ms. Shubhangi Agarwal is proposed to be appointed for a term of five (5) consecutive years, to conduct the Secretarial Audit of five consecutive financial years from 2025-26 to 2029-30.

The proposed fees payable to Ms. Shubhangi Agarwal is mutually agreed between company and secretarial auditor. The Audit Committee/ Board are proposed to be authorised to revise the fee, from time to time.

The Board of Directors recommends the said resolution, as set out in item 3 of this Notice for your approval.

None of the Directors or key managerial personnel or their relatives is in any way concerned or interested, financially or otherwise in the said resolution.

Ms. Monika Joshi (DIN: 10652494) be and is hereby re-designated and appointed as "Managing Director" (also, a "Whole-time Key Managerial Personnel") of the Company with effect from September 30, 2025 till the end of her current tenure upto September 04, 2029 and that the other terms and conditions of her appointment including remuneration as approved at the 14th AGM of the company held on September 30, 2024 shall remain unchanged."

ITEM NO 4

Mr. Pritesh Champalal Doshi (DIN: 05155318) was appointed as Whole Time Director at the 10th Annual General Meeting ("AGM") of the Company held on 30th September, 2021 for five years from 01.04.2021 to 31.03.2026.

The Company does not have Whole Time Director after the re-designation of Ms. Monika Joshi Whole Time Director to Managing Director and therefore based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, subject to the approval of members of the Company, has considered and approved to re-designate Mr. Pritesh Champalal Doshi as Whole Time Director with effect from 30.09.2025 for remaining tenure of the current appointment up to 31.03.2026 on the same terms and conditions as approved at 10th AGM held on 30th September, 2021.

Mr. Pritesh Champalal Doshi, has confirmed that he has not been disqualified under section 164 and Schedule V of the Companies Act, 2013 and also given a declaration that he has not been disqualified or debarred from being appointed or continuing Director of the Company by virtue of any SEBI order or any other authority.

The brief profile of Mr. Pritesh Champalal Doshi in terms of Regulation 36 of the Listing Regulations and Clause 1.2.5 of Secretarial Standard-2, is: Mr Pritesh Doshi Joined Looks Health Services Limited as Manager Since 2012 overall supervisor, administrator and control head of the Looks. He has an expert vision when it comes to the health services. He also plays a huge role in the strategic decision-makings, overall growth and development of the organization. He seamlessly manages the various business functions like advising, staffing, communicating etc. He also dedicates his time on taking effective measures towards top health services of the organization. He is also gifted with excellent operational and client management skills. He operates collaboratively with the team members to achieve a common goal of the group.

Save and except Mr. Pritesh Champalal Doshi, being appointee none of the other Directors/Key Managerial Personnel (KMP) of the Company/their relatives is, in any way, concerned or interested, financially or otherwise, in the resolution set out at item no. 4 of the notice.

The Board of Directors recommends the Special Resolution as set out at item no. 4 of the Notice for approval by the shareholders.

ITEM NO 5

Ms. Monika Joshi (DIN: 10652494) was appointed as Managing Director at the 13th Annual General Meeting ("AGM") of the Company held on 30th September, 2024 for five years from 05.09.2024 to 04.09.2029.

The Company does not have Managing Director after the re-resignation of Mr. Pritesh Champalal Doshi and therefore based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, subject to the approval of members of the Company, has considered and approved to re-designate Ms. Monika Joshi as Managing Director with effect from 30.09.2025 for remaining tenure of the current appointment up to 04.09.2029 on the same terms and conditions as approved at 13th AGM held on 30th September, 2024.

Ms. Monika Joshi, has confirmed that she has not been disqualified under section 164 and Schedule V of the Companies Act, 2013 and also given a declaration that she has not been disqualified or debarred from being appointed or continuing Director of the Company by virtue of any SEBI order or any other authority.

The brief profile of Ms. Monika Joshi in terms of Regulation 36 of the Listing Regulations and Clause 1.2.5 of Secretarial Standard-2, is: Ms. Monika Joshi is a graduate. She is having the Demonstrates strong problem solving skills and the ability to work effectively both independently and as a part of team.

Save and except Ms. Monika Joshi, being appointee none of the other Directors/Key Managerial Personnel (KMP) of the Company/their relatives is, in any way, concerned or interested, financially or otherwise, in the resolution set out at item no. 5 of the notice.

The Board of Directors recommends the Special Resolution as set out at item no. 5 of the Notice for approval by the shareholders.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED

SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN: 10652494

DATE: 04.09.2025
PLACE: MUMBAI

DIRECTORS' REPORT

Dear Member,

The Directors present this 14th Annual Report of Looks Health Services Limited (the Company) along with the audited financial statements for the financial year ended March 31, 2025.

In compliance with the applicable provisions of Companies Act, 2013, (including any statutory modification(s) or re-enactment(s) thereof, for time being in force) ("Act") and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this report covers the financial results and other developments during the financial year ended on 31st March, 2025, in respect of Looks Health Services Limited.

1. FINANCIAL HIGHLIGHTS & STATE OF AFFAIRS:

1.1 The financial performance of the Company for the financial year ended 31st March, 2025 is summarized below:

(Rs. In Lakhs)

Particulars	Year Ended On 31.03.2025	Year Ended On 31.03.2024
Revenue from operations	39.47	0.00
Other Income	39.05	45.76
Total Revenue	78.52	45.76
Operating and Administrative expenses	61.47	33.95
Operating Profit before finance costs, Depreciation and Tax	17.06	11.81
Less: Depreciation and Amortization expenses	14.17	14.17
Profit before finance costs, exceptional items, tax and Deff tax adjustable in/(recoverable from) future tariff	2.89	(2.36)
Less: Finance Costs	0.00	0.00
Less: Exceptional Item	0.00	0.00
Profit Before Tax (PBT)	2.89	(2.36)
Provision for Tax (Including Deferred Tax)	0.50	(0.59)
Profit after Tax	2.39	(1.77)
Other Comprehensive Income	0.00	0.00
Total Comprehensive Income for the year	0.00	0.00
Profit available for appropriation	2.39	(1.77)
Retained earning	19.86	(18.09)
Add: Profit for the year	2.39	(1.77)
Add: Securities premium	450.00	450.00
Add/(Less) Other Comprehensive Income /(Loss)	0.00	0.00
Dividend paid/ to be paid on equity shares	0.00	0.00
Other Equity closing balance	432.53	430.14

PERFORMANCE HIGHLIGHTS:

A. REVENUE: During the year under review, the Company recorded revenue from operations amounting to Rs. 39.47 lakhs, as compared to NIL in the previous year, reflecting a significant improvement in operational performance.

B. OPERATING AND ADMINISTRATIVE EXPENSES: The operating Expenses of Rs. 61.47 Lakhs during FY 2024-25, as compared to previous financial year 2023-24 incurred of Rs. 33.95 lakhs.

C. DEPRECIATION AND AMORTISATION EXPENSES: The depreciation expense remains unchanged at ₹14.17 lakhs, the same as in the previous financial year 2023-24.

D. TOTAL PROFIT BEFORE AND AFTER TAX FOR THE YEAR: The profit before tax of Rs. 2.89 Lakhs during FY 2024-25, as compared to previous financial year 2023-24 loss before tax of Rs. 2.36 lakhs. The profit after tax of Rs. 2.39 Lakhs during FY 2024-25 as compared to previous financial year 2023-24 loss after tax of Rs. 1.77 lakhs.

E. TRANSFER TO RESERVES: The Board of Directors have decided to retain the entire amount of profit for F.Y. 2024-25 in the Statement of Profit & Loss as at March 31, 2025.

2. DIVIDEND:

During the period under review, the Board of Directors does not recommend any dividend.

3. STATEMENT OF DEVIATION OR VARIATION

During the period under review, disclosures relating to deviations or variations in the terms of a public issue, rights issue, preferential issue, etc., are not applicable to the Company, as no shares or other securities were issued during the year.

4. BUY-BACK OF SHARES:

During the period under review, no shares were bought back by the Company.

5. DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

During the period under review, there were no shares in the demat suspense account or unclaimed suspense account.

6. EMPLOYEE STOCK OPTION SCHEME (ESOP):

The Company does not have any Employee Stock Option Scheme (ESOP).

7. HUMAN RESOURCES DEVELOPMENT: -

Continuous efforts are put in to improve the working environment with a focus on employee well-being and capability building enabling them to perform at their best for the Company. We provide robust leadership development efforts to hone employee skills and help keep the Company ahead of the curve. People are our real strength and therefore while pursuing best-in-class performance; the Company is significantly increasing its investment in its employees with training and development. The Company invests in training and knowledge.

8. TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

In accordance with the provisions of Sections 124 and 125 of the Companies Act, 2013 and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"), dividends of a company which remain unpaid or unclaimed for a period of seven years from the date of transfer to the Unpaid Dividend Account shall be transferred by the company to the Investor Education and Protection Fund ("IEPF").

In terms of the foregoing provisions of the Companies Act, 2013, there is no dividend which remains outstanding or remains to be paid and require to be transferred to the IEPF by the Company during the year under review.

Dividend Declared for the Last Years: **N.A.**

Due date for transfer to IEPF, of the unclaimed/unpaid dividends are as under: **N.A.**

9. SHARE CAPITAL:

During the year under review, the Company has not altered/modified its authorised share capital and has not issued any shares. The Company has not issued any sweat equity shares to its directors or employees.

The Paid-up Share Capital of the Company as on 31st March, 2025 is Rs. 10,50,00,000/- divided into 1,05,00,000 Equity Shares of Rs. 10/- each fully paid up.

During the year under review, the Company has not issued shares with differential voting rights. As on March 31, 2025, none of the Directors of the Company holds instruments convertible into equity shares of the Company.

10. RESERVES AND SURPLUS:

The Company has transferred amount of the surplus of P & L account for the financial year ended 31st March, 2025.

11. MANAGEMENT DISCUSSION & ANALYSIS REPORT:

Management's Discussion and Analysis Report for the year under review, as stipulated under Regulation 34 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015 (LODR Regulation) read with Schedule V thereto, is forms part of this Annual Report as **ANNEXURE- 1**

12. CORPORATE GOVERNANCE:

The Company has been complying with the principles of good Corporate Governance over the years and is committed to the highest standards of compliance. Pursuant to Regulation 34(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 a report on Corporate Governance forms an integral part of this Annual Report as **ANNEXURE 2.**

13. CORPORATE SOCIAL RESPONSIBILITY (CSR):

During the financial year under review, the provisions related to CSR were not applicable to the Company.

14. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There were no material changes and commitments affecting the financial position of the Company which have occurred between the end of the financial year ended 31st March, 2025 to which the Financial Statements relates and the date of signing of this report.

15. RISK MANAGEMENT POLICY:

Pursuant to Regulation 21(5) of SEBI (LODR) Regulations, 2015, the company does not fall under list of Top 1000 companies and thus the company is not required to frame Risk Management Policy mandatorily.

The Company has a well-defined risk management framework in place. The Company has established procedures to periodically place before the Audit Committee and the Board, the risk assessment and minimization procedures being followed by the Company and steps taken by it to mitigate these risks.

16. VIGIL MECHANISM / WHISTLE BLOWER POLICY FOR DIRECTORS AND EMPLOYEES:

The Company has formulated a comprehensive Whistle Blower Policy in compliance with the provisions of Section 177(9) and 177(10) of The Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 with a will to enable the stakeholders, including directors, individual employees to freely communicate their concerns about illegal or unethical practices and to report genuine concerns to the Audit Committee of the Company. The policy on Vigil Mechanism has been uploaded on the Company's website: <https://looksclinic.in/>.

17. INFORMATION REQUIRED UNDER SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

The Company has in place a policy on prevention, prohibition and redressal of Sexual Harassment at workplace in line with the requirements of The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Internal Complaints Committee has been setup to redress the complaints received on the sexual harassment. All employees of the Company are covered under this policy.

During the period under review, no complaints on sexual harassment were received.

18. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis. No Material Related Party Transactions, entered during the year by your Company as per Section 188 of the Companies Act, 2013 which require approval of the member. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) of the Companies Act, 2013 in Form AOC-2 is not applicable. Further disclosure of transactions with related parties is set out as part of the financial statements.

The Policy on materiality of related party transactions and also on dealing with related party transactions as approved by the Board may be accessed on the website of the Company at the link <https://looksclinic.in/>

19. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE COMPANIES ACT, 2013:

Pursuant to Section 186 of the Companies Act, 2013, disclosure on particulars relating to loans, advances, guarantees and investments are provided as part of the financial statements to the Members of LOOKS HEALTH SERVICES LIMITED of even date of Standalone Financial Statements.

20. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE FINANCIAL YEAR:

During the period under review, there was no application made or any proceeding pending under The Insolvency & Bankruptcy Code, 2016 against/by the company.

21. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF DURING THE FINANCIAL YEAR:

During the period under review, there was no valuation done in the company as there is no such incident of one-time settlement.

22. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS:

During the period under review, there were no significant / material orders passed by the regulators or courts or tribunals, impacting the going concern status and Company's operations in future.

23. ANNUAL RETURN:

Pursuant to Section 92(3) and 134(3) (a) of the Companies Act, 2013 the Annual Return of the Company prepared in accordance with Section 92(1) of the Companies Act, 2013 read with Rule 11 of the Companies (Management and Administration) Rules, 2014 (as amended), is placed on the website of the Company and is accessible at the web-link <https://looksclinic.in/>.

24. CREDIT RATING:

During the year under review, the requirement of credit rating of securities of company was not applicable and hence no credit rating has been undertaken.

25. PUBLIC DEPOSITS:

The Company has not accepted any deposits falling within the meaning of Section 73 or 74 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 during the financial year under review and as such, no amount on account of principal or interest on deposits from public was outstanding as on 31st March, 2025.

26. SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE:

During the year under review, the company is not having any subsidiary, associates or joint venture.

27. CHANGE IN NATURE OF BUSINESS:

During the year under review, there has been no change in the Company's nature of business.

28. DIRECTORS:

During the year under review, the Board of the Company is duly constituted. None of the directors of the Company is disqualified under the provisions of the Companies Act, 2013 or the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018.

In accordance with the provisions of the Companies Act, 2013 and Articles of Association of the Company, **MS. MONIKA JOSHI (DIN: 10652494), Whole Time Director, retires by rotation and being eligible**, offers herself for reappointment at the ensuing AGM. Her appointment is placed for approval of the members and forms part of the notice of the 14th AGM. The information about the Director seeking her reappointment as per Para 1.2.5 of Secretarial Standards on General Meetings and Regulation 36 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 has been given in the notice convening the 14th AGM.

29. KEY MANAGERIAL PERSONNEL:

Pursuant to Section 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the following are the Key Managerial Personnel of the Company as on 31st March, 2025:

- i. Mr. Pritesh Champalal Doshi, Managing Director;
- ii. Ms. Monika Joshi, Whole Time Director;
- iii. Mr. Milinath Gavas, Chief Financial Officer.

The changes in the key managerial personnel are provided in corporate information of the annual report for the year 2024-25.

The remuneration and other details of these Key Managerial Personnel for Financial Year 2024-25 are provided in the Annual Return which is available on the website of the Company.

30. COMMITTEES:

As per the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018, the following committees were constituted and the composition, meeting of committees held during the year are as follows.

i. Audit Committee:

The Composition of the Audit Committee is as follows:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	02.01.2012	-	5/3
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	5/3
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	5/3
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	5/2
5	Ms. Monika Joshi	Member (Whole Time Director)	05.09.2024	-	5/2
6	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	5/2

During the financial year 2024-25, Audit Committee met Five times on 30th May, 2024, 29th July, 2024, 05th September, 2024, 14th November, 2024 and 13th February, 2025.

ii. Nomination and Remuneration Committee:

The Composition of the Nomination and Remuneration Committee is as follows:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	02.01.2012	-	2/1
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	2/1
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	2/1
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	2/1
5	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	2/1
6	Mr. Mihir Ganappa	Member (Non-Executive Director)	05.09.2024	-	2/1

During the financial year 2024-25, Nomination and Remuneration Committee met two times on 05th September, 2024 and 17th February, 2025.

iii. Stakeholders Relationship Committee:

The Composition of the Stakeholders Relationship Committee is as follows:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	02.01.2012	-	2/1
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	2/1
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	2/1
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	2/0
5	Ms. Monika Joshi	Member (Whole Time Director)	05.09.2024	-	2/0
6	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	2/0

During the financial year 2024-25, Stakeholders Relationship Committee met two time on 05th September, 2024 & 13th February, 2025.

31. INTERNAL FINANCIAL CONTROLS:

Internal Financial Controls and their Adequacy

In terms of Section 134(5)(e) of the Companies Act, 2013, the term Internal Financial Control means the policies and procedures adopted by a company for ensuring orderly and efficient conduct of its business, including adherence to company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting records, and timely preparation of reliable financial information.

Internal Control over Financial Reporting (ICFR) remains an important component to foster confidence in a company's financial reporting, and ultimately, streamlining the process to adopt best practices. The Company through Internal Audit Program is regularly conducting test of effectiveness of various controls. The ineffective and unsatisfactory controls are reviewed and remedial actions are taken immediately. The internal audit plan is also aligned to the business objectives of the Company which is reviewed and approved by the Audit Committee. Further, the Audit Committee monitors the adequacy and effectiveness of the Company's internal control framework.

Adequate internal financial controls are in place which ensures the reliability of financial and operational information. The regulatory and statutory compliances are also ensured.

Internal Control systems and their Adequacy

The Company has Internal Control Systems, commensurate with the size, scale and complexity of its operations. The Internal Auditor monitors and evaluates the efficacy and adequacy of internal control systems in the Company, accounting procedures and policies within the Company. Based on the report of internal audit function, process owners undertake corrective action in respective areas and thereby strengthen the controls. Significant observations and corrective actions thereon are presented to the Audit Committee from time to time.

32. AUDITORS:

A. Statutory Auditors

The board of directors of the company has accepted the resignation of M/s Parekh Shah & Lodha, Chartered Accountants (FRN: 107487W) with effect from the resignation letter dated August 14, 2024. The board of directors of the company has appointed M/s. KPSJ & Associate LLP, Chartered Accountants (Firm Registration No. 124845W), to fill the casual vacancy w.e.f. September 05, 2024 subject to the approval of the members in 13th AGM. In the 13th AGM approval of the members accorded to appoint M/s. KPSJ & ASSOCIATES LLP, Chartered Accountants, Ahmedabad, having FRN.: 124845W, as the Statutory Auditors of the Company to conduct the statutory audit for a period of five years commencing from the conclusion of this 13th Annual General Meeting till the conclusion of 18th Annual General Meeting of the Company

B. Statutory Audit Report

There are no qualifications, reservations or adverse remarks made by M/S KPSJ & Associates & LLP, Statutory Auditors (having Firm Registration Number is 124845W/W100209), in their report for the financial year ended 31st March, 2025.

C. Consolidated Financial Statements

The Directors are pleased to present the Consolidated Financial Statements, prepared in accordance with the Accounting Principles generally accepted in India, and in compliance with Section 129(3) of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018, as amended from time to time.

As per Section 129(3) of the Companies Act, 2013, the audited Consolidated Financial Statements form part of this Annual Report. Accordingly, the note regarding non-applicability is not required.

D. Internal Auditor

M/s Dhruvaparakash & Co., who is the Internal Auditor, has carried out internal audit for all the quarter of financial year 2024-25. Their reports were reviewed by the Audit Committee.

E. Cost Auditor

During the Financial Year 2024-25, your Company is not required to maintain cost records under Companies (Cost Records and Audit) Rules, 2014.

F. Secretarial Auditor and Secretarial Audit

Pursuant to the Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/S **VKM & Associates**, Company Secretaries, Mumbai as the Secretarial Auditors of the Company to undertake the Secretarial Audit of the Company for the FY 2024-25.

The Secretarial Audit Report in form MR-3 is annexed of the Directors' Report as **ANNEXURE-3**. The report does not contain any qualification, reservation, adverse remark or disclaimer.

G. Annual Secretarial Compliance Report

Annual Secretarial Compliance Report under regulation 24A of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 ("SEBI LODR") read with SEBI Circular dated February 08, 2019 number CIR/CFD/CMDI/27/2019, is applicable to the Company. Annual Secretarial Compliance Report given by the M/S **VKM & Associates**, PCS and uploaded on BSE.

H. Reporting of Frauds by Auditors:

During the year under review, the Statutory Auditors, Internal Auditors, ~~Cost Auditors~~ and Secretarial Auditors have not reported any instance of fraud committed in the Company by its Officers or Employees to the Audit Committee under Section 143(12) of the Companies Act, 2013 and the rules made thereunder.

33. MEETINGS OF THE BOARD AND COMMITTEES:

During the Financial Year 2024-25, the Board of Directors met ten (10) times and the details of the meetings of the Board and its Committees are given in the Corporate Governance Report **(ANNEXURE 2)**.

The gap intervening between two meetings was within the time prescribed under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018.

Details of attendance of meetings of the Board:

During the financial year 2024-25, Ten Board Meetings were held on **30TH MAY, 2024, 29TH JULY, 2024, 05TH SEPTEMBER, 2024, 01ST OCTOBER, 2024, 24TH OCTOBER, 2024, 14TH NOVEMBER, 2024, 28TH NOVEMBER, 2024, 30TH JANUARY, 2025, 13TH FEBRUARY, 2025, and 17TH FEBRUARY, 2025**. The composition of the Board, attendance at the Board Meetings during the year ended on 31st March, 2025 and the last Annual General Meeting and also the number of other directorships and Committee memberships are given below:

Name of the Director	Category	Attendance particular 2024-25				
		Board Meeting held During tenure of Director	Board Meeting Attended	Last AGM Attend or Not	No. of Directorship in other Public Ltd. Cos	Chairman-Membership in other public Limited Cos
Mr. Pritesh Champalal Doshi	Managing Director	10	10	Yes	0	0
Ms. Sejal Hitesh Jain	Independent Director	10	10	Yes	0	0
Mr. Krishna Mukesh Sangani resign w.e.f. 30.09.2024	Independent Director	3	3	Yes	0	0
Ms. Monika Joshi Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024 and appoint as WTD	Whole Time Director	7	7	No	2	0
Mr. Mihir Ganappa Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Non-Executive Director	7	7	No	0	0
Mr. Dhruv Pravinbhai Rajgor Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Independent Director	7	7	Yes	0	0
Mr. Bhavin Mahendrakumar Hirpara Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Independent Director	7	7	Yes	0	0

Details of attendance of meetings of Committees and the Annual General Meeting are included in the Report on Corporate Governance, which forms part of this Annual Report.

34. MEETING OF INDEPENDENT DIRECTORS:

In terms of requirements under Schedule IV of the Companies Act, 2013 and Regulation 25 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018, The independent directors of the listed entity shall hold at least one meeting in a financial year, without the presence of non-independent directors and members of the management and all the independent directors shall strive to be present at such meeting.

During the financial year under review, the Independent Directors of the Company met on **March 21, 2025** inter-alia, to discuss:

- Evaluation of performance of Non-Independent Directors and the Board of Directors of the Company as a whole.
- Evaluation of performance of the Chairman of the Company, taking into view of Executive and Non-Executive Directors.
- Evaluation of the quality, content and timelines of flow of information between the Management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

35. DECLARATION BY INDEPENDENT DIRECTORS:

The Company has received declarations from each Independent Director of the Company under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time confirming compliance with the criteria of independence as stipulated under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time and there has been no change in the circumstances which may affect their status as Independent Directors during the year 2024-25.

All Independent Directors of the Company have affirmed compliance with the Schedule IV of the Companies Act, 2013 and Company's Code of Conduct for Directors and Employees for the Financial Year 2024-25.

All the Independent Directors of the Company have registered themselves with the Indian Institute of Corporate Affairs ('IICA') towards the inclusion of their names in the data bank maintained with it and they have not appeared for proficiency self-assessment test during the period under review.

36. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent / Non- Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

37. FAMILIARISATION PROGRAMME FOR INDEPENDENT DIRECTORS:

The Familiarization program aims to provide insight to the Independent Directors to understand the business of the Company. Upon induction, the Independent Directors are familiarized with their roles, rights and responsibilities.

All the Directors of the Company are updated as and when required, of their role, rights, responsibilities under applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time, Secretarial Standards; nature of industry in which the Company operates, business model of the Company, etc. The Company holds Board and the Committee Meetings from time to time. The Board of Directors has complete access to the information within the Company. The Independent Directors have the freedom to interact with the Company's management. Directors are also informed of the various developments in the Company through various modes of communications. All efforts are made to ensure that the Directors are fully aware of the current state of affairs of the Company and the industry in which it operates.

The details of the familiarization programme undertaken have been uploaded on the Company's website: <https://looksclinic.in/>.

38. PERFORMANCE EVALUATION OF BOARD AND ITS COMMITTEES:

The Board of Directors has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time.

The performance of the board was evaluated by the Board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the committees was evaluated by the Board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc.

The above criteria are broadly based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India on January 5, 2017. In a separate meeting of independent directors, performance of non-independent directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of executive directors and non-executive directors.

The Board and the Nomination and Remuneration Committee reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.

At the board meeting that followed the meeting of the independent directors and meeting of Nomination and Remuneration Committee, the performance of the Board, its Committees, and individual directors was also discussed. Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated.

39. DIRECTORS' APPOINTMENT AND REMUNERATION POLICY:

The Company has on the recommendation of the Nomination & Remuneration Committee framed and adopted a Nomination and Remuneration Policy in terms of the Section 178 of the Companies Act, 2013 with effect from 24th April, 2025. The policy, inter alia lays down the principles relating to appointment, cessation, remuneration and evaluation of directors, key managerial personnel and senior management personnel of the Company.

The policy on The Nomination & remuneration Policy of the Company and other matters provided in Section 178(3) of the Companies Act, 2013 has been annexed as **ANNEXURE 4**.

The Nomination & Remuneration Policy of the Company is on the website of the Company: <https://looksclinic.in/>.

40. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

The details as required under Section 197(12) of the Companies Act, 2013 and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given in **ANNEXURE-5** of this Report.

The information required under Section 197(12) of Companies Act, 2013 read with Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, including amendment thereto, is provided in the **ANNEXURE-5** forming part of the Report.

During the year, the Company had no employee who was employed throughout the Financial Year or part thereof and was in receipt of remuneration, which in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the Managing Director or Whole-Time Director or Manager and holds by himself or along with his spouse and dependent children, not less than 2% of the equity shares of the Company.

41. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

In accordance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 (as amended), the requirement to submit a Business Responsibility Report has been discontinued from the financial year 2022-23 onwards. Instead, the top 1,000 listed companies based on market capitalization as on 31st March of the relevant financial year are required to submit a Business Responsibility and Sustainability Report (BRSR), in the format prescribed by SEBI Circular No. SEBI/HO/CFD/CMD-2/P/CIR/2021/562 dated 10th May, 2021.

As our Company does not fall within the top 1,000 listed entities based on market capitalization as per the BSE list as on 31st March 2025, the requirement to submit the BRSR for the financial year 2024-25 is not applicable.

42. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information pertaining to details of conservation of energy, technology absorption, foreign exchange earnings and outgo as required under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8 of the Companies Accounts Rules, 2014 are as follows:

A) Conservation of energy:

As required by Rule 8 to Companies (Account Rules, 2014),

- Company ensures that the operations of the Company are conducted in the manner where by optimum utilization and maximum possible savings of energy is achieved.
- No specific investments have been made for reduction in energy consumption.

B) Technology Absorption:

The Company continues to take prudential measures in respect of technology absorption, adaptation and take innovative steps to use the scarce resources effectively. Further, the company has not incurred any expenses towards Research & Development.

C) Foreign Exchange earnings and Outgo:

The Particulars of Foreign Exchange and Outgo for the year under review are as follows:

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Foreign Exchange Earning	39,47,136	-
Foreign Exchange Outgo	-	-

43. DIRECTORS' RESPONSIBILITY STATEMENT:

The Directors' Responsibility Statement referred to in Section 134 (3) (c) of the Companies Act, 2013 shall state that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and profit of the Company for that period;
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the directors had prepared the annual accounts on a going concern basis;
- (e) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

44. SECRETARIAL STANDARDS:

The Company is in compliance with the Secretarial Standards on Meetings of Board of Directors (SS-1) and General Meetings (SS-2) issued by the Institute of Company Secretaries of India.

45. PROHIBITION OF INSIDER TRADING:

In terms of the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended (PIT Regulations), the Company has adopted the revised "Code of Conduct to Regulate, Monitor and Report Trading by Insiders" ("the Code"). The Code is applicable to all Directors, Designated persons and connected Persons and their immediate relatives, who have access to unpublished price sensitive information relating to the Company.

The Company has also formulated 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)' in compliance with the PIT Regulations.

The aforesaid Codes are posted on the Company's website and can be accessed by using web link at: <https://looksclinic.in/>.

46. STATEMENT REGARDING OPINION OF THE BOARD WITH REGARD TO INTEGRITY, EXPERTISE AND EXPERIENCE (INCLUDING THE PROFICIENCY) OF THE INDEPENDENT DIRECTORS APPOINTED DURING THE YEAR:

In the opinion of Board of Directors of the Company, Independent Directors on the Board of Company hold highest standards of integrity and are highly qualified, recognized and respected individuals in their respective fields. It's an optimum mix of expertise (including financial expertise), leadership and professionalism.

47. CEO/CFO CERTIFICATION:

As required under Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time, the Managing Director and CFO of the Company have certified the accuracy of the Financial Statements and adequacy of Internal Control Systems for financial reporting for the year ended 31st March, 2025. The certificate is annexed in ANNEXURE-6.

48. DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT:

The Code of Conduct of the Company aims at ensuring consistent standards of conduct and ethical business practices across the Company. This Code is reviewed on an annual basis and the latest Code is available on the website of the Company at web link <https://looksclinic.in/>.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 as amended from time to time, a confirmation from the Managing Director regarding compliance with the Code by all the Directors and senior management of the Company is annexed in ANNEXURE-7.

49. REGISTERED OFFICE OF THE COMPANY:

During the period under review, the Registered Office of the Company was shifted from its present address - 5 & 9, Floor-1 & 2, Plot-27/33, Beaumon Chambers, Nagindas Master Lane, Hutatma Chowk, Fort, Mumbai City, Mumbai, Maharashtra, India, 400001 to 35, Floor-2, Plot-3/5, Seth Lalji Dayal Building, Dadi Seth Agiary Lane, Malharrao wadi, Kalbadevi, Mumbai-400002, Maharashtra, India with effect from 28th November, 2024.

50. CAUTIONARY STATEMENT:

The Annual Report including those which relate to the Directors' Report, Management Discussion and Analysis Report may contain certain statements on the Company's intent expectations or forecasts that appear to be forward-looking within the meaning of applicable securities laws and regulations while actual outcomes may differ materially from what is expressed herein. The Company bears no obligations to update any such forward looking statement. Some of the factors that could affect the Company's performance could be the demand and supply for Company's product and services, changes in Government regulations, tax laws, forex volatility etc.

51. ACKNOWLEDGEMENT:

The Directors take this opportunity to thank the shareholders, bankers and the financial institutions for their cooperation and support to the operations and look forward for their continued support in future. The Directors also thank all the customers, vendor partners, also mention government and government authorities and other business associates for their continued support during the year. The Directors place on record their appreciation for the hard work put in by all employees of the Company.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
PRITESH CHAMPAL DOSHI
MANAGING DIRECTOR
(DIN : 05155318)**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
(DIN: 10652494)**

**DATE: 04.09.2025
PLACE: MUMBAI**

ANNEXURE- 1

MANAGEMENT DISCUSSION AND ANALYSIS:

1. **Industry Structure and Development:** The global economic graph saw some of the worst plunges in 2020-2021 because of the situation of COVID 19 Pandemic and the effects are still being reflected in the financial year 2024-2025. However, the pro activeness shown by most of the Governments through stimulus and aggressive vaccination drives allowed most nations to tide over the worst and witness rekindled growth going forward. With the changing dimension of beauty, influence of media, film industry and fashion, the market is predicted to fuel over in the near future. Health factors such as rise in accidents and obesity and people have become more prone about their health which has led to the growth of the market. Moreover, technological factors which include the development of advanced materials like silicone implants is also expected to spur the market growth in domestic as well as in global market. Moreover, with the increasing popularity of digital photography, introduction to self-monitoring apps, high demand to increase one's self-esteem and affordability of cosmetic surgeries in developing countries can substantially increase the volume of cosmetic surgery procedures.

India is viewed as one of the most progressive countries for cosmetic surgical procedures and this trend is expected to continue in the near future. This is mainly due to the fact that cosmetic surgery has evolved beyond the traditional concept of being a risky or impractical procedure that was demanded by women who were overly conscious about their appearance. Today, people in India understand that cosmetic surgery is a highly specialized and advanced niche of plastic surgery that helps people attain happiness with fewer risks and greater affordability.

In the past, cosmetic surgeries in India were associated with celebrities and people of the affluent class. However, today, these surgeries are increasingly becoming popular and are being undertaken by the middle class. Increasingly, both men and women from the upper middle class group are opting for cosmetic procedures to look attractive in order to get lucrative jobs, best possible marriage partners and primarily get rid of any deformity that they feel impacts their self confidence and self-esteem. Moreover, traditionally, men and women in their late 20s and early 30s were the key clients of cosmetic surgeons. However, a new trend has emerged where teenagers are approaching cosmetic/ aesthetic surgeons to get some cosmetic procedure done.

The changing lifestyle and urbanization, growing awareness of cosmetic surgery procedures, availability of better infrastructure and the rising economic capacity are all driving the cosmetic surgeries market in India.

2. **Opportunities & Threats:** The Cosmetics market is especially rich in opportunities since most products still have low penetration rates among the population. For instance, only 40% of households use skin care products out of which women are more prone on using such products for their skin health. Company is continuously looking for opportunities of growth in new areas and ventured into some revenue generating services that can boost financial health of the company. The global cosmetic surgery market is projected to grow from \$46.02 billion in 2021 to \$58.78 billion in 2028 at a CAGR of 3.6% in forecast period 2021-2028.

As per research findings, cosmetics market, once female dominated, has started earning high revenues from male counterparts as well, by catering to male-specific needs. The revenue generated through male cosmetic market has increased the total revenue of Indian cosmetic industry.

Meanwhile, the recent COVID 19 pandemic, social taboos against body part violation, non-essential nature of cosmetic surgery and high cost associated with such surgeries are some of the major factors restricting the market growth in domestic as well as in global market.

3. **Segment wise performance:** Company operates only in one segment viz. Cosmetic & Non Cosmetic Treatments.
4. **Outlook:** The effects of COVID-19 pandemic effects are showing recovery on a slow pace and growth of businesses across the world. Our business was disrupted too with the initial lockdowns leading to closure of both of our Clinics situated at Goa and Mumbai. The company is taking all necessary measures to re-open clinics as soon possible and start carrying out the operations in order to achieve impressive realization of opportunities in the market.
5. **Risks & Concerns:** The COVID-19 pandemic, along with subsequent lockdown measures and market disruptions, has had a significant impact on the industry, leading to the temporary closure of all our clinics and a pause in active operations.

Nonetheless, the underlying demand for services related to hair loss, scalp concerns, and skin conditions continues to persist. People will continue to seek professional guidance and effective treatment solutions. While our clinics are currently non-operational, the Company is actively working towards gradual revival and is committed to resuming operations in a phased and sustainable manner.

The management has identified key risks including regulatory changes, competitive pressures, supply chain disruptions, cyber and data security challenges, high capital requirements, and broader economic and political uncertainties. The Company recognizes that risks are an inherent part of any business and is focused on proactively identifying, managing, and mitigating them. Although economic downturns present ongoing challenges, the long-term prospects of the cosmetic and wellness industry remain promising. With appropriate mechanisms in place, the Company is taking steps to overcome current challenges and position itself for future growth and resilience.

6. **Internal Control System & their Adequacy:** The Company has a well-defined system of internal audit. It is in place so as to independently review and strengthen the internal controls. The Audit Committee of the Company reviews the reports of the internal auditors quarterly and recommends steps for further improvement of the internal controls. They ensure that assets are safeguarded and protected against loss or unauthorized disposal. It is also designed for effectiveness and efficiency of operations, compliance or regulations backed by strong audit framework at all the locations.
7. **Cautionary Statement:** Statements in the Management Discussion and Analysis describing the Company's objectives, projections, estimates, expectations may be forward-looking statements. Actual results may differ materially from those expressed or implied due to various risks and uncertainties. Important factors that could make a difference to the Company's operations include economic and political condition in India and in the countries in which the Company operates volatility in currency rates, changes in Government regulations and policies, tax laws, statutes and other incidental factors. The Company does not undertake to update these statements.
8. **Financial Performance:**
 - **Share Capital:** The Paid up Share Capital of the Company as on 31st March, 2025 stands at Rs. 10,50,00,000/- divided into 1,05,00,000 equity shares of Rs. 10/- each fully paid up.
 - **Reserves and Surplus:** The Reserves and Surplus is Rs. 432.53 lakhs as on the end of financial year.
 - **Total Income:** During the year under consideration, total income is Rs. 78.52 Lakhs.
9. **Employee Relations:** Company has smooth relations with its employees during the year under review.
10. **Our Strategy:** The pandemic restrictions led the closure of both the clinics in Mumbai & Goa. Company is developing strategies in order to re-open the clinic as soon as possible. Further the company is looking into cost management and new targeted expansion since the economy has started gaining strength. Company is highly dedicated in searching for new place for expansion and bringing the business prospects of the Company back to life.

Material Development in Human Resource

Ratios	FY 2024-25	FY 2023-24	Change %	Reason
Debtors Turnover	0	0	0	No debtors outstanding
Inventory Turnover	N.A.	N.A.	N.A.	--
Interest Coverage Ratio	N.A.	N.A.	N.A.	--
Current Ratio	7.33	32.36	-77.34%	Due to increase in current liabilities (On Account of Provision of Tax as Company earned Net Profit) result in Decrease in Current Ratio 31.03.2025
Debt Equity Ratio	-	-	N.A.	--
Net Profit Ratio	6.05%	N.A.	N.A.	Due to company has provided Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25
Return on Net Worth/Return on capital employed %	0.20%	-0.16%	221.88%	Due to company has resumed providing Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25

The Company's Human Resource Development's efforts aim to make Looks a preferred place to work. This is being achieved through various initiatives including skill development, personality enhancement and employee engagement through internal communications to foster happiness at work.

11. **Details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore:**
Details of any change in Return on Net Worth as compared to the immediately previous financial year along with a

detailed explanation thereof:

Return on Net worth FY 2024-25: 0.20%
Return on Net worth FY 2023-24: -0.16%

Return on Net worth is increased by 221.88% during the Financial Year 2024-2025.

REGISTERED OFFICE:

**35, FLOOR-2, PLOT-3/5, SETH LALJI DAYAL BUILDING,
DADI SETH AGIARY LANE, MALHARRAO WADI, KALBADEVI,
MUMBAI-400002, MAHARASHTRA, INDIA**

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN NO.: 10652494**

**DATE: 04.09.2025
PLACE: MUMBAI**

ANNEXURE- 2

CORPORATE GOVERNANCE REPORT:

[Pursuant to Part C of Schedule V to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

The Directors present the Company's Report on Corporate Governance for the financial year 2024-25. This report elucidates the systems and processes followed by the Company to ensure compliance of corporate governance requirements under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") and the Companies Act, 2013 ("Act").

The Corporate Governance signifies the role of the management as the trustees to the property of the shareholders and acceptance of the inherent rights of the shareholders by the management. Corporate Governance is a framework which helps various participants' viz. shareholders, Board of Directors and Company's management, in shaping company's performance and the way it is preceding towards attainment of its goals.

I. COMPANY'S PHILOSOPHY:

The Company's Corporate Governance philosophy encompasses not only regulatory and legal requirements, such as the terms of SEBI Listing Regulations, but also several voluntary practices at a superior level of business ethics, effective supervision and enhancement of shareholders' value.

The Company believes that timely disclosures, transparent accounting policies and a strong and independent board go a long way in protecting the shareholders' interest while maximizing long term corporate values.

The Company is in compliance with the requirements on the Corporate Governance stipulated under SEBI Listing Regulations.

II. BOARD OF DIRECTORS:

Composition of the Board

The Company has a balanced board with optimum combination of Executive and Non-Executive Directors, including independent directors, which plays a crucial role in Board processes and provides independent judgment on issues of strategy and performance.

As on the year ended, The Board of Directors of your Company comprises of 6 (Six) Directors out of which 4 (Four) Directors (66.67%) are Non-Executive Directors. The 2 (Two) Executive Director include the Managing Director and Whole Time Director. Out of the 6 (Six) there are 4(Four) Non-Executive Directors i.e. 3(three) are non-executive independent director (out of 3(three) one is non-executive independent women director) and 1(one) is non-executive director and 2(two) is executive director which is managing director and Whole time Director of the company. No Director is related to each other.

Independent directors are Non-Executive directors as defined under Regulation 16(1) (b) of the SEBI Listing Regulations. The maximum tenure of the independent Directors is in compliance with the Companies Act, 2013. All the Independent Directors have confirmed that they meet the criteria as mentioned under regulation 16(1)(b) of the SEBI Listing Regulation and Section 149 of the Companies Act, 2013. The present strength of the Board reflects judicious mix of professionalism, competence and sound knowledge, which enables the Board to provide effective leadership to the Company.

None of the Directors on the Company's Board is a Member of more than 10 (ten) Committees, and Chairman of more than 5 (five) Committees (Committees being, Audit Committee and Stakeholders' Relationship Committee) across all the companies in which he/she is a Director. All the Directors have made necessary disclosures regarding Committee positions held by them in other companies and do not hold the office of Director in more than 10 (ten) public companies as on March 31, 2025.

The composition of the Board is in conformity with the Regulation 17 of the SEBI Listing Regulations read with Section 149 of the Companies Act, 2013.

None of the Directors have attained the age of Seventy-five (75) years.

The Board is of the opinion that Independent Directors fulfill conditions specified under the Listing Regulations and are independent of the management of the Company.

Meetings and attendance

During the financial year 2024-25, Ten Board Meetings were held on **30TH MAY, 2024, 29TH JULY, 2024, 05TH SEPTEMBER, 2024, 01ST OCTOBER, 2024, 24TH OCTOBER, 2024, 14TH NOVEMBER, 2024, 28TH NOVEMBER, 2024, 30TH JANUARY, 2025, 13TH FEBRUARY, 2025, and 17TH FEBRUARY, 2025**. The composition of the Board, attendance at the Board Meetings during the year ended on 31st March, 2025 and the last Annual General Meeting and also the number of other directorships and Committee memberships are given below:

Name of the Director	Category	Attendance particular 2024-25				
		Board Meeting held During tenure of Director	Board Meeting Attended	Last AGM Attend or Not	No. of Directorship in other Public Ltd. Cos	Chairman-Membership in other public Limited Cos
Mr. Pritesh Champalal Doshi	Managing Director	10	10	Yes	0	0
Ms. Sejal Hitesh Jain	Independent Director	10	10	Yes	0	0
Mr. Krishna Mukesh Sangani resign w.e.f. 30.09.2024	Independent Director	3	3	Yes	0	0
Ms. Monika Joshi Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024 and appoint as WTD	Whole Time Director	7	7	No	0	0
Mr. Mihir Ganappa Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Non-Executive Director	7	7	No	0	0
Mr. Dhruv Pravinbhai Rajgor Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Independent Director	7	7	Yes	0	0
Mr. Bhavin Mahendrakumar Hirpara Appoint as Additional Director w.e.f. 05.09.2024 and regularize in AGM held on 30.09.2024	Independent Director	7	7	Yes	0	0

* In accordance with the provisions of the Listing Regulations, directorships held in Private Limited and Foreign Companies have been excluded. Directorship in listed entities excluding Looks Health Services Limited is shown.

** In accordance with the provisions of the Listing Regulations, 2015, memberships/ chairpersonships of only Audit Committee and Stakeholders' Relationship Committee in all public limited companies excluding Looks Health Services Limited have been considered.

Details of name of other entities where Directors of the Company are Directors and the category of Directorship as on March 31, 2025 are as under:

NAME OF THE DIRECTOR	NAME OF OTHER ENTITIES IN WHICH THE CONCERNED DIRECTOR IS A DIRECTOR	TYPE OF COMPANY (LISTED/UNLISTED PUBLIC/PRIVATE)	CATEGORY OF DIRECTORSHIP
Mr. PRITESH CHAMPALAL DOSHI	Faraway Places Marketing Private Limited Maxgainz Finserve Private Limited Sur-Man Securities Private Limited Rribada Films Private Limited	Private Company	Director WTD Director Director
MS. SEJAL HITESH JAIN	NIL	NIL	NIL
MS. MONIKA JOSHI	NIL	NIL	NIL
MR. MIHIR GANAPPA	NIL	NIL	NIL
MR. DHURUV PRAVINBHAI RAJGOR	NIL	NIL	NIL
MR. BHAVIN MAHENDRAKUMAR HIRPARA	NIL	NIL	NIL

Information to the Board

A detailed agenda folder is sent to each director in advance of the Board Meetings. As a policy, all major decisions, in addition to matters which statutorily require the approval of the Board are put up for consideration of the Board. Pursuant to Regulation 17(7) of the SEBI Listing Regulations, the agenda includes the minimum information required to be placed before the board of directors. All the agenda items are backed by necessary supporting information and documents (except for the critical price sensitive information, which is circulated separately or placed at the meeting) to enable the Board to take informed decisions.

The Board periodically reviews compliance certificate of laws applicable to the Company, prepared by the management as well as steps taken by the company to rectify instances of non-compliances, if any.

Disclosure of relationship between directors inter-se:

No Any directors are related to each other.

Shareholding of Non-Executive Directors:

Details of shares held by the Non-executive directors of the Company as on 31st March, 2025 are as under:

Sr no.	Name Of Non-Executive Director	No. of equity shares held in the Company	No. of convertible instruments held in the Company
1	Ms. Sejal Hitesh Jain	0	There is no convertible instruments issued by the Company.
2	Mr. Mihir Ganappa	0	
3	Mr. Dhruv Pravinbhai Rajgor	0	
4	Mr. Bhavin Mahendrakumar Hirpara	0	

Certificate of Non Disqualification of Directors from Practicing Company Secretary:

In terms of the Listing Regulations, 2015, **Mr. Vijay Kumar Mishra** partner of M/S VKM & Associates, Company Secretaries, has issued a certificate that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as Directors of the Companies by SEBI / Ministry of Corporate Affairs or any other statutory authority. The certificate forms part of Corporate Governance Report and is given in **Annexure-A**.

Declaration of Independence

All the Independent Directors have submitted a declaration of independence, stating that they meet the criteria of independence provided under section 149(6) of the Act, as amended, and regulation 16(1)(b) and 25 of the SEBI Listing Regulations. The Independent Directors have also confirmed compliance with the provisions of Rule 6 of Companies (Appointment and Qualifications of Directors) Rules, 2014, as amended, relating to inclusion of their name in the databank of independent directors maintained by Indian Institute of Corporate Affairs.

Chart/Matrix Setting Out the Skills/Expertise/Competence of the Board of Directors:

A chart/ matrix setting out the core skills/ expertise/ competencies identified by the Board of Directors in the context of the Company's businesses and sectors as required for it to function effectively and those actually available with the Board along with skills / expertise / competence, possessed by the Board members of the Company as on 31st March, 2025, are given as below:

Mapping of the skills / expertise / competence actually available with the Board along with the names of Directors, is given below:

Business Leadership	Leadership experience including in areas of business development, strategic planning, succession planning, driving change and long-term growth and guiding the Company and its senior management towards its vision and values.
Financial Expertise	Knowledge and skills in accounting, finance, treasury management, tax and financial management of large corporations with understanding of capital allocation, funding and financial reporting processes
Risk Management	Ability to understand and assess the key risks to the organization, legal compliances and Ensure that appropriate policies and procedures are in place to effectively manage risk.
Global Experience	Global mindset and staying updated on global market opportunities, competition experience in driving business success around the world with an understanding of diverse business environments, economic conditions and regulatory frameworks
Corporate Governance	Experience in implementing good corporate governance practices, reviewing compliance and governance practices for a sustainable growth of the company and protecting stakeholder's interest.
Technology & Innovations	Experience or knowledge of emerging areas of technology such as digital, artificial intelligence, cyber security, data center, data security etc.

Areas of Skills/ Expertise						
Name of Director	Business Leadership	Financial Expertise	Risk Management	Global Experience	Corporate Governance	Technology & Innovation
Mr. Pritesh Doshi	√	√	√		√	
Ms. Sejal Jain	√				√	
Ms. Monika Joshi	√	√				
Mr. Mihir Ganappa	√	√				
Mr. Dhruv Pravinbhai Rajgor	√	√		√		
Mr. Bhavin Mahendrakumar Hirpara	√	√	√	√		√

Note - Each Director may possess varied combinations of skills/ expertise within the described set of parameters and it is not necessary that all Directors possess all skills/ expertise listed therein.

Independent Directors:

Independent Directors play a pivotal role in maintaining a transparent working environment in the Company.

They provide valuable outside perspective to the deliberations of the Board and contribute significantly to the decision-making process. They help the Company in improving corporate credibility and governance standards. They bring an element of objectivity to the board processes and deliberations.

As per Regulation 25(3) of the Listing Regulations, 2015, a separate meeting of Independent Directors of the Company without the attendance of Non-Independent Directors for the financial year 2024-25 is held on **21ST MARCH, 2025**.

During the year, no Independent director has resigned before the expiry of his/her tenure.

Employee Stock Option Scheme:

The Company does not have any Employee Stock Option Scheme (ESOS).

Management Discussion and Analysis

Management Discussion and Analysis is given in a separate section forming part of the Board's Report in this Annual Report.

Code of Conduct

The Board of Directors has laid down the Codes of Conduct ('Code'), for the all the Board members and senior management of the company.

These Codes have been posted on the Company's website i.e. www.looksclinic.in. All the Board Members and Senior Management personnel of the Company have affirmed Compliance with the Code of Conduct as applicable to them, for the year ended March 31, 2025. A declaration to this effect signed by **Mr. Pritesh Champalal Doshi, Managing Director** is annexed to this Report as **Annexure 7**.

Familiarization Programme for Independent Directors:

The Familiarization program aims to provide insight to the Independent Directors to understand the business of the Company. Upon induction, the Independent Directors are familiarized with their roles, rights and responsibilities.

All the Directors of the Company are updated as and when required, of their role, rights, responsibilities under applicable provisions of the Companies Act and the SEBI Listing Regulations, Secretarial Standards; nature of industry in which the Company operates, business model of the Company, etc. The Company holds Board and the Committee Meetings from time to time. The Board of Directors has complete access to the information within the Company. The Independent Directors have the freedom to interact with the Company's management. Directors are also informed of the various developments in the Company through various modes of communications. All efforts are made to ensure that the Directors are fully aware of the current state of affairs of the Company and the industry in which it operates.

The details of the familiarization programme undertaken have been uploaded on the Company's website and web link of Familiarization Programme for Independent Directors as on Company Website: www.looksclinic.in.

Performance Evaluation of Board and its Committees:

The Board of Directors has carried out an annual evaluation of its own performance, board committees, and individual directors pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations.

The performance of the board was evaluated by the Board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the committees was evaluated by the Board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc.

The above criteria are broadly based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India on January 5, 2017. In a separate meeting of independent directors, performance of non-independent directors, the Board as a whole and Chairman of the Company was evaluated, taking into account the views of executive directors and non-executive directors.

The Board and the Nomination and Remuneration Committee reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.

At the board meeting that followed the meeting of the independent directors and meeting of Nomination and Remuneration Committee, the performance of the Board, its Committees, and individual directors was also discussed. Performance evaluation of independent directors was done by the entire Board, excluding the independent director being evaluated.

Performance evaluation criteria for independent directors:

The Independent Directors shall be evaluated on the basis of the following criteria;

General:

- a. Qualifications:** Details of professional qualifications of the member.
- b. Experience:** Details of prior experience of the member, especially the experience relevant to the entity
- c. Knowledge and Competency:**
 - i. How the person fares across different competencies as identified for effective functioning of the entity and the Board (The entity may list various competencies and mark all directors against every such competency)
 - ii. Whether the person has sufficient understanding and knowledge of the entity and the sector in which it operates.
- d. Fulfillment of functions:** Whether the person understands and fulfills the functions to him/her as assigned by the Board and the law (E.g. Law imposes certain obligations on independent directors)
- e. Ability to function as a team:** Whether the person is able to function as an effective team- member
- f. Initiative:** Whether the person actively takes initiative with respect to various areas
- g. Availability and attendance:** Whether the person is available for meetings of the Board and attends the meeting regularly and timely, without delay.
- h. Commitment:** Whether the person is adequately committed to the Board and the entity

i. Contribution: Whether the person contributed effectively to the entity and in the Board meetings

j. Integrity: Whether the person demonstrates highest level of integrity (including conflict of interest disclosures, maintenance of confidentiality, etc.)

Additional criteria for Independent director:

a. Independence: Whether person is independent from the entity and the other directors and there if no conflict of interest.

b. Independent views and judgment: Whether the person exercises his/ her own judgment and voices opinion freely.

The Non-Independent Directors along with the Independent Directors, except the one who is being evaluated, will evaluate/assess each of the Independent Directors on the aforesaid parameters. On the basis of the report of performance evaluation, it shall be determined whether to extend or continue the term of appointment of the Independent Director.

REMUNERATION OF DIRECTORS:

Pecuniary Relationship of Non-Executive Directors

The Company has no pecuniary relationship or transaction with its Non-Executive and Independent Directors other than payment of sitting fees to them for attending Board and committee meetings and commission as approved by members and Board for their invaluable services to the Company.

i. Non-Executive Directors:

The Non-Executive Director(s) of the Company are remunerated in way of sitting fees, if any. Sitting fees is paid to the Non-Executive Directors for attending the meetings of Board of Directors, Committees of Board of Directors and other meetings of Directors at the rate of decided by the board from time to time respectively per meeting.

ii. Executive Directors:

The One Executive Directors (Chairman/Managing Director/Whole-time Director) are paid remuneration as decided by the Board of Directors on the recommendation of the Nomination and Remuneration Committee of the Board, with the approval of the Shareholders and other necessary approvals.

iii. Details of remuneration paid to the Directors for the year ended 31st March, 2025.

During the period under review, there is remuneration paid to the directors and key managerial personnel.

NAME OF KMP	REMUNERATION PAID DURING THE F.Y. 2024-25(IN LAKHS)
PRITESH DOSHI	0.90
CS KANCHAN KAKU	7.56
MILINATH GAVS	2.40

There are no stock options available/ issued to any non-executive Directors of the Company. N.A.

The Company has not granted any stock options to the directors and hence, it does not form part of the remuneration package payable to any Director.

III. BOARD COMMITTEES

Pursuant to SEBI Listing Regulations / Companies Act, there were three Committees as on March 31, 2025 viz. Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee. All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of reference / role of the Committees are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and attendance at meetings, are provided below.

➤ **AUDIT COMMITTEE:**

The Audit Committee acts as a link among the Management, the Statutory Auditors, Internal Auditors and the Board of Directors to oversee the financial reporting process of the Company. The Committee's purpose is to oversee the quality and integrity of accounting, auditing and financial reporting process including review of the internal audit reports and action taken report.

Meeting, Attendance, Constitution & Composition of Audit Committee:

The Audit Committee is duly constituted in accordance with the Listing Agreement read with SEBI (LODR) Regulations 2015 and of Section 177 of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014. It adheres to the terms of reference which is prepared in compliance with Section 177 of the Companies Act, 2013, and SEBI (LODR) Regulations 2015.

During the year under review, Audit Committee Meetings were held Five times on 30th May, 2024, 29th July, 2024, 05th September, 2024, 14th November, 2024 and 13th February, 2025. The intervening gap between two meetings did not exceed 120 days.

The Composition of the Audit Committee and details of attendance of the members at the committee meetings during the year are given below:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	24.12.2011	-	5/3
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	5/3
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	5/3
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	5/2
5	Ms. Monika Joshi	Member (Whole Time Director)	05.09.2024	-	5/2
6	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	5/2

Ms Kanchan Kaku appoint as company secretary of the company upto 17th February, 2025.

The Company Secretary is also Secretary to the Audit Committee.

There has been no instance, where the Board has not accepted any recommendation of Audit Committee.

Broad Terms of Reference:

The powers, role and terms of reference of the Audit Committee covers the areas as contemplated under the SEBI Listing Regulations and Section 177 of the Companies Act, 2013. The brief terms of reference of Audit Committee are as under:

- Oversight of the company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommendation for appointment, remuneration and terms of appointment of auditors of the company;
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors;
- Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:
 1. Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of Section 134(5)(c) read with Section 134(3)(c) of the Companies Act, 2013
 2. Changes, if any, in accounting policies and practices and reasons for the same
 3. Major accounting entries involving estimates based on the exercise of judgment by management
 4. Significant adjustments made in the financial statements arising out of audit findings
 5. Compliance with listing and other legal requirements relating to financial statements
 6. Disclosure of any related party transactions
 7. Modified opinion(s) in the draft audit report
- Reviewing, with the management, the quarterly financial statements before submission to the board for approval;
- Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter;
- Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- Approval or any subsequent modification of transactions of the company with related parties; **if applicable**
- Scrutiny of inter-corporate loans and investments, company, **wherever it is necessary**;
- Valuation of undertakings or assets of the company, **wherever it is necessary**;
- Evaluation of internal financial controls and risk management systems;
- Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;
- Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
- Discussion with internal auditors of any significant findings and follow up there on;
- Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors; **if applicable**.
- To review the functioning of the Whistle Blower mechanism;
- Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
- Carrying out any other function as is mentioned in the terms of reference of the Audit Committee;
- Reviewing financial statements, in particular the investments made by the Company's unlisted subsidiaries;

Review of Information by Audit Committee:

- The Management discussion and analysis of financial condition and results of operations;
- Statement of significant related party transactions submitted by management.
- Management letters / letters of internal control weaknesses issued by the statutory auditors;
- Internal audit reports relating to internal control weaknesses;
- The appointment, removal and terms of remuneration of the Chief Internal Auditor; and
- Statement of deviations:
 1. Quarterly statement of deviation(s) including report of monitoring agency, **if applicable, submitted to stock exchange(s).N.A.**

2. Annual statement of funds utilized for purposes other than those stated in the offer documents / prospectus/notice if applicable: N.A.

➤ **NOMINATION AND REMUNERATION COMMITTEE:**

Meeting, Attendance, Constitution & Composition of Nomination and Remuneration Committee

The Nomination and Remuneration Committee is constituted in compliance with the requirements of Listing Agreement read with SEBI (LODR) Regulations 2015 and Section 178 of the Companies Act, 2013 read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014. The Company Secretary acts as the Secretary to the committee and the Committee Members are independent and non-executive directors.

During the year under review, Nomination and Remuneration Committee Meetings were held two times on 05th September, 2024 and 17th February, 2025.

The composition of the Nomination & Remuneration Committee and details of meetings attended by the members are given below:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	24.12.2011	-	2/1
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	2/1
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	2/1
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	2/1
5	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	2/1
6	Mr. Mihir Ganappa	Member (Non-Executive Director)	05.09.2024	-	2/1

Ms Kanchan Kaku appoint as company secretary of the company upto 17th February, 2025.

The Company Secretary is also Secretary to the Nomination and Remuneration Committee.

Broad Terms of Reference

The powers, role and terms of reference of Committee covers the areas as contemplated under the SEBI Listing Regulations and Section 178 of the Companies Act, 2013. The brief terms of reference of Nomination and Remuneration Committee are as under:

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a Director and recommend to the Board a policy relating to the remuneration of the directors, key managerial personnel and other employee;
2. Formulation of criteria for evaluation of performance of Independent Directors and the Board;
3. Devising a policy on Board diversity;
4. Identifying persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board their appointment and removal and shall carry out evaluation of every director's performance;
5. To extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
6. To recommend/review remuneration of the Managing Director(s) and Whole time Director(s)/Executive Director(s) based on their performance and defined assessment criteria;
7. To carry out any other function as is mandated by the Board from time to time and/or enforced by any statutory notification, amendment or modification, as may be applicable;
8. To perform such other functions as may be necessary or appropriate for the performance of its duties;
9. To recommend to the board, all remuneration, in whatever form, payable to senior management.

➤ **STAKEHOLDERS RELATIONSHIP COMMITTEE/ SHARE TRANSFER COMMITTEE/ INVESTOR GRIEVANCE COMMITTEE:**

Meeting, Attendance, Constitution & Composition of Investor Grievance Committee

The Share Transfer cum Investors'/ Shareholders' Grievance Committee comprise of three members. The Committee looks into the redressal of investors' complaints such as delay in transfer of equity shares, request for transmission of shares, issue of duplicate share certificates, non-receipt of declared dividends/ annual reports etc.

During the year under review, Share Transfer cum Investors'/ Shareholders' Grievance Committee Meetings were two time on 05th September, 2024 & 13th February, 2025.

The composition of the Stakeholders Relationship Committee and details of meetings attended by the members are given below:

Sr. No	Name of the Members	Status	Date of appointment	Date of resignation	Number of meetings held/attended
1	Mr. Pritesh Champalal Doshi	Member (Managing Director)	24.12.2011	-	2/1
2	Ms. Sejal Hitesh Jain	Chairman (Independent Director)	01.04.2021	-	2/1
3	Mr. Krishna Mukesh Sangani	Member (Independent Director)	10.08.2023	30.09.2024	2/1
4	Mr. Dhruv Pravinbhai Rajgor	Chairperson (Independent Director)	05.09.2024	-	2/0
5	Ms. Monika Joshi	Member (Whole Time Director)	05.09.2024	-	2/0
6	Mr. Bhavin Mahendrakumar Hirpara	Member (Independent Director)	05.09.2024	-	2/0

Ms Kanchan Kaku appoint as company secretary of the company upto 17th February, 2025.

The Company Secretary is also Secretary to the Stakeholders Relationship Committee.

Broad Terms of Reference

The powers, role and terms of reference of Stakeholders Relationship Committee covers the areas as contemplated under the SEBI Listing Regulations and Section 178 of the Act. The brief terms of reference of Stakeholders Relationship Committee are as under:

1. Resolving the grievances of the security holders including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.
2. Reviewing the measures taken for effective exercise of voting rights by shareholders.
3. Reviewing of adherence to the service standards adopted in respect of various services being rendered by the Registrar & Share Transfer Agent.
4. Reviewing the various measures and initiatives taken for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company.
5. Carry out any other function as is referred by the Board from time to time or enforced by any statutory notification / amendment or modification as may be applicable.

Investor Grievance Redressal

Details of complaints received and redressed during the year:

Number of complaints received and resolved during the year under review and their breakup are as under:

Nature of Complaints	Complaint received	Complaint resolved
Non-receipt of refund order	0	0
Non-receipt of dividend warrants	0	0
Non-receipt of annual report	0	0
Non-receipt / credit of shares	0	0
TOTAL	0	0

IV. DISCLOSURE:

(a) Related Party Transactions

During the period under review, The Company has not entered into material contracts or arrangements or transactions with related parties in accordance with Section 188 of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014.

There were materially significant Related Party Transactions not made by the Company during the year that would have not required shareholders' approval under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018.

The Policy on materiality of related party transactions and dealing with related party transactions is formulate the Policy on materiality of related party transactions and upload on website and to give the web link is: www.looksclinic.in

The Related Party Transactions were placed before the Audit Committee for prior approval, as required under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 if required. A statement of all Related Party Transactions was placed before the Audit Committee for its review on a quarterly basis, specifying the nature and value of the transactions as and when required.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2018 is not required to annex with this report because of there is no any related party transaction made during the period under review by the company.

(b) Accounting treatment in preparation of financial statements

The Company has followed the IND-AS Accounting standards notified by The Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, read with Companies (Indian Accounting Standards) Amendment Rules, 2016 in preparation of its financial statements.

(c) Risk Management

The Risk management process is designed to safeguard the Organization from various risks through adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in order to minimize its impact on the business. The potential risks are inventoried and integrated with the management process such that they receive the necessary consideration during decision making. It is dealt with in greater details in the management discussion and analysis section.

The Company has a competent Internal Audit System which prepares and executes a vigorous audit plan covering various functions such as purchase audit, factory payroll audit, operations, finance, human resources, administration, statutory dues etc. across different factories. The internal auditor presents their key audit findings of every quarter to the Audit Committee. The management updates the members about the remedial actions taken or proposed for the same. The suggestions and comments from the Committee members are vigilantly incorporated and executed by the Company.

As per the Regulation of 21 of SEBI LODR Regulation, 2015 shall be applicable to: the top 1000 listed entities, determined on the basis of market capitalization as at the end of the immediate preceding financial year i.e. 2024-25; and high value debt listed entity. **Our Company is not in the list of top 1000 listed entities as on 31st March, 2025. So, this regulation is not applicable.**

(d) Subsidiary Companies

As on March 31, 2025, the Company doesn't have any subsidiary.

(e) Code for Prevention of Insider Trading Practices

As per SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has adopted a Code of Conduct for Prevention of Insider Trading & Code of Corporate Disclosure Practices. All the Directors, employees and third parties such as auditors, consultants etc. who could have access to the unpublished price sensitive information of the Company are governed by this code. The trading window is closed during the time of declaration of results and occurrence of any material events as per the code. The Company has appointed Company Secretary, as Compliance Officer, who is responsible for setting forth procedures and implementation of the code for trading in company's securities. Company has complied with provisions of Regulation 3(5) and 3(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, during the year under review.

(f) Whistle Blower Policy/ Vigil Mechanism

The Company has formulated a comprehensive Whistle Blower Policy in line with the provisions of Section 177(9) and 177(10) of the Act and Regulation 22 of the Listing Regulations with a will to enable the stakeholders, including directors, individual employees to freely communicate their concerns about illegal or unethical practices and to report genuine concerns to the Audit Committee of the Company. Web link of the policy unloaded on company website i.e. www.looksclinic.in.

(g) CEO/CFO Certification

As required under Regulation 17 (8) of the SEBI Listing Regulations, the CEO & CFO of the company have certified regarding the financial statements for the year ended March 31, 2025 which is annexed to this Report.

(h) Pledge of Equity Shares:

All the promoters' shareholding is free from any encumbrance.

(i) Disclosure of Pending Cases/Instances of Non- Compliance

There were no non-compliances by the Company and no instances of penalties and strictures imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to the capital market during the last three years.

(j) Details of compliance with mandatory requirements and adoption of the non-mandatory requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

- i. **Details of non-compliance, if any:** There is no Non-Compliance of any requirement of Corporate Governance Report of sub para (2) to (10) of the Part C of Schedule V of the SEBI Listing Regulations except the mentioned in the Form MR-3.
- ii. **Compliance with mandatory requirements:** The Company has complied with all the mandatory items of the SEBI (Listing Obligations and Disclosures Requirement) Regulations, 2015 except the mentioned in the Form MR-3.

(k) Compliance report on discretionary requirements under Regulation 27(1) of SEBI Listing Regulations:

- i. **The Board:** The Chairman of the company is an executive director and maintains the chairman's office at the company's expenses for performance of his duties.
- ii. **Shareholders' Rights:** The Company did not send quarterly results to each household of the shareholders in financial year 2024-25 but uploaded on Stock exchange i.e. BSE limited. However, in addition to displaying its quarterly results on its website www.looksclinic.in and publishing in widely circulated newspapers.
- iii. **Audit Qualifications:** The auditors have not qualified the financial statements of the company.
- iv. **Reporting of Internal Audit:** The Internal Auditor regularly updates the audit committee on internal audit findings at the audit committee meetings.

V. MEANS OF COMMUNICATION:

In accordance with Regulation 46 of the SEBI Listing Regulations, the company has maintained a functional website at www.looksclinic.in containing information about the Company viz., details of its business, financial information, shareholding pattern, compliance with corporate governance, details of the policies approved by the Company, contact information of the designated officials of the Company who are responsible for assisting and handling investor grievances etc. The contents of the said website are updated from time to time.

The annual financial results are published in the leading English newspaper "Business standard" and Marathi newspaper "Mumbai Lakshadeep". The said results are promptly furnished to the Stock Exchanges for display on their respective websites and also displayed on the Company's website.

Further, the Company disseminates to the Stock Exchange (i.e. BSE), wherein its equity shares are listed, all mandatory information and price sensitive/ such other information, which in its opinion, are material and/or have a bearing on its performance/ operations and issues press releases, wherever necessary, for the information of the public at large.

VI. GENERAL BODY MEETINGS:

The date, time and location of the Annual General Meetings held during the preceding 3 (three) years and special resolutions passed there at are as follows:

F.Y.	Date	Location Of Meeting	Time	No. Of Special Resolution Passed
2023-24	30.09.2024	At Registered Office at 5 & 9, Floor – 1 & 2, Plot - 27/33, Beaumon Chambers, Nagindas Master Lane, Hutatma Chowk, Fort, Mumbai – 400001	11:30 A.M.	Four Special Resolutions were passed
2022-23	29.09.2023	At Registered Office at 5 & 9, Floor – 1 & 2, Plot - 27/33, Beaumon Chambers, Nagindas Master Lane, Hutatma Chowk, Fort, Mumbai – 400001	09:30 A.M.	No Special Resolutions were passed
2021-22	30.09.2022	At Registered Office at 5 & 9, Floor – 1 & 2, Plot - 27/33, Beaumon Chambers, Nagindas Master Lane, Hutatma Chowk, Fort, Mumbai – 400001	02:30 P.M.	No Special Resolutions were passed

The Extra Ordinary General Meetings held during the year 2024-25 is: NIL

No ordinary resolution was required to be put through postal ballot during the year 2024-25.

No special resolution was required to be put through postal ballot during the year 2024-25.

No special resolution is proposed to be conducted through postal ballot.

VII. GENERAL SHAREHOLDER INFORMATION:

1. Date, Time and Venue of the Annual General Meeting:

Date: 30.09.2025

Time: 11:00 A.M.

Place: Through VC/OAVM

2. Last date for Receipt of Proxies: In terms of the relaxations granted by MCA and SEBI, the facility for appointment of proxies by Members will not be available at the ensuing AGM.

3. Financial Calendar for the FY 2025-2026:

Subject Matter	Dates of Board meeting for Financial Results (Published on or before)
Result for Quarter ending 30th June, 2025	14th August, 2025
Result for Quarter ending 30th September, 2025	14th November, 2025
Result for Quarter ending 31st December, 2025	14th February, 2026
Result for Quarter ending 31st March, 2026	30th May, 2026

4. Dates of Book Closure:

19.09.2025 to 30.09.2025 (both days inclusive).

5. Dividend Record Date: N.A., Dividend payment dates: N.A.

6. The name and address of each stock exchange(s) at which the listed entity's securities are listed and a confirmation about payment of annual listing fee to each of such stock exchange:

The Company's Equity Shares are listed on the following Stock Exchanges: BSE Limited, P.J. Towers, Dalal Street, Fort, Mumbai - 400 001. The Company has paid the Listing Fees for the year 2024-25 and 2025-26 to BSE Limited where the Company's equity shares are listed.

7. Stock Code: BSE: 534422, ISIN: INE204N01013

8. Corporate Identification Number: Corporate Identity Number (CIN) of the Company, allotted by the Ministry of Corporate Affairs, Government of India is L93030MH2011PLC222636.

9. Stock market price data- high, low during each month in last financial year:

MONTH	HIGH	LOW	CLOSE
APRIL 2024	6.62	4.41	6.50
MAY 2024	6.49	5.25	5.70
JUNE 2024	6.44	5.24	6.25
JULY 2024	6.69	5.25	5.35
AUGUST 2024	5.59	4.90	5.24
SEPTEMBER 2024	5.59	4.86	5.03
OCTOBER 2024	5.63	4.66	5.38
NOVEMBER 2024	5.60	4.17	4.85
DECEMBER 2024	5.49	4.76	5.09
JANUARY 2025	5.35	4.42	4.69
FEBRUARY 2025	5.58	4.18	4.97
MARCH 2025	5.40	3.81	4.64

10. There was no suspension from trading in equity shares of the Company during the year 2024-25.

11. Registrar to an issue and share transfer agents

The Company has appointed Skyline Financial Services Pvt. Ltd as Registrar and Share Transfer Agent (RTA). Shareholders/ Investors / Depository Participants are requested to send all their documents and communications pertaining to demat shares to the RTA at the following address:

During the year under review

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

A/505 Dattani Plaza, Andheri Kurla Road, Safeed Pool, Andheri (East), Mumbai - 400072

Tel: 022-49721245, 022-28511022 Email: admin@skylinerta.com

12. **Share transfer system:** In terms of the Listing Regulations, securities of listed companies can only be transferred in dematerialized form with effect from 1st April, 2019. In view of the same, the 100% of the share capital of the Company is in dematerialized form. The shares can be transferred by shareholders through their Depository Participants after dematerialize his/her shares.

13. Distribution of shareholding as on 31st March, 2025:

(a) Based on Shares held as on March 31, 2025

Shareholding of nominal (in Rs.)	No. of shareholder	% of total	Share amount	% of total
1-5000	9430	79.75	11689330.00	11.13
5001-10000	1147	9.70	9528210.00	9.07
10001-20000	613	5.18	9286490.00	8.84
20001-30000	244	2.06	6140850.00	5.85
30001-40000	98	0.83	3526980.00	3.36
40001-50000	69	0.58	3248740.00	3.09
50001-100000	132	1.12	10193780.00	9.71
100001 & above	92	0.78	51385620.00	48.94
TOTAL	11825	100.00	105000000.00	100.00

(b) Shareholding Pattern as on March 31, 2025:

S.N.	Category	No. of shareholders	No. of shares	%
A	Promoters/ Promoter Group	2	2122500	20.21
B	Public			
1	Institutions			
a	Mutual Funds	0	0	0
b	Venture Capital Funds	0	0	0
c	Alternate Investment Funds	0	0	0
d	Banks	0	0	0
e	Insurance Companies	0	0	0
f	Provided Fund	0	0	0
g	Asset Reconstruction Companies	0	0	0
h	Sovereign Wealth Fund	0	0	0
i	NBFCs registered with RBI	0	0	0
j	Other financial institution	0	0	0
k	Any other	0	0	0
	Sub-Total (B)(1)	0	0	0
2	Institutions- Foreign			
a	Foreign Direct Investment	0	0	0
b	Foreign Venture Capital Investors	0	0	0
c	Sovereign Wealth Fund	0	0	0
d	Foreign Portfolio Investors Category I	0	0	0
e	Foreign Portfolio Investors Category II	0	0	0
f	Overseas Depositories	0	0	0
g	Any other	0	0	0
	Sub-Total (B)(2)	0	0	0
3	Central Government / State Government			
a	Central Government / President of India	0	0	0
b	State Government / Governor	0	0	0
c	Shareholding by companies or bodies corporate where central / state government is a promoter	0	0	0
	Sub-Total (B)(2)	0	0	0
4	Non-institutional			

a	Associate companies/Subsidiaries	0	0	0
b	Directors and their relatives (excluding independent directors and nominee directors)	0	0	0
c	Key Managerial Personnel	0	0	0
d	Relatives of promoters (other than 'immediate relatives' of promoters disclosed under 'Promoter and Promoter Group' category)	0	0	0
e	Trusts where any person belonging to 'Promoter and Promoter Group' category is 'trustee', 'beneficiary', or 'author of the trust'	0	0	0
f	Investor Education and Protection Fund (IEPF)	0	0	0
g	Individual shareholders holding nominal share capital up to Rs. 2 lakhs	11527	5770442	54.96
h	Individual shareholders holding nominal share capital in excess of Rs. 2 lakhs	42	2224068	21.18
i	Non Resident Indians (NRIs)	8	19123	0.18
j	Foreign Nationals	0	0	0
k	Foreign Companies	0	0	0
l	Bodies Corporate	10	286942	2.73
m	Any Other (specify)	61	76925	0.73
	Sub-Total (B)(4)	11648	8377500	79.79
	Total Public Shareholding(B)= (B)(1)+(B)(2)+ (B)(3)+ (B)(4)	11648	8377500	79.79
	Grant Total (A)+(B)	11650	10500000	100.00

14. **Dematerialization of shares and liquidity:** As on 31st March, 2025, 100% of the Company's Equity Shares have been dematerialized.
15. **Outstanding GDRs/ADRs/ Warrants or any Convertible instruments, conversion date and likely impact on equity:** Not applicable.
16. **Plant locations:** N.A.
17. **Address for correspondence:**
The Registered Office
35, Floor-2, Plot-3/5, Seth Lalji Dayal Building, Dadi Seth Agiary Lane, Malharrao wadi, Kalbadevi, Mumbai-400002, Maharashtra, India
CIN: L93030MH2011PLC222636
Website www.looksclinic.in
Email id: lookshealthserv@gmail.com
18. **Credit ratings along with any revisions thereto during the relevant financial year:** Not applicable.
19. **Commodity price risk and Commodity hedging activities:** Not applicable.
20. **Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A):** Not applicable.
21. **A certificate from a Company Secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/ Ministry of Corporate Affairs or any such statutory authority.** The Certificate of Company Secretary in practice is annexed herewith as a part of the report.
22. **Where the board had not accepted any recommendation of any committee of the board which is mandatorily required, in the relevant financial year:** Not Applicable
23. **Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditor and all entities in the network firm/network entity of which the statutory auditor is a part:** Details relating to fees paid to the Statutory Auditors are given in Note to the Standalone Financial Statements.
24. **Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013**
No. of Complaints filed during the financial year- Nil
No. of Complaints disposed of during the financial year – Nil
No. of Complaints pending as on end of the financial year – Nil

25. The following is the list of core skills/expertise/competencies identified by the Board of Directors as required in the context of its business(es) and sector(s) for it to function effectively and those actually available with the Board: i) Knowledge - understand the Company's business, policies, and culture (including its mission, vision, values, goals, current strategic plan, governance structure, major risks and threats and potential opportunities) and knowledge of the industry in which the Company operates, ii) Behavioral Skills- attributes and competencies to use their knowledge and skills to function well as team members and to interact with key stakeholders, iii) Strategic thinking and decision making, iv) Financial Skills, v) Technical/ Professional skills and specialized knowledge to assist the ongoing aspects of the business.

VIII. COMPLIANCE:

- Auditors' Certificate on Corporate Governance:** Certificate from the Company Secretary in Practice towards compliance of the provisions of Corporate Governance, forms an integral part of this Annual Report annexed as **Annexure -8**
- DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT**
Pursuance to Schedule V (F) of SEBI Listing Regulations, the information in respect of equity shares, which were issued in public issue and remain unclaimed and are lying in the suspense account, in demat, are as follow:

PARTICULARS	NO. OF SHAREHOLDERS	NO OF SHARES
Aggregate number of shareholders and the outstanding shares in the suspense account lying on April 1, 2024	NIL	NIL
Number of shareholders who approached to the Company for transfer of shares from suspense account during the year.	NIL	NIL
Number of shareholders to whom shares were transferred from suspense account during the year	NIL	NIL
Aggregate number of shareholders and the outstanding shares in the suspense account laying on March 31, 2025	NIL	NIL

Voting rights on above shares shall remain frozen till the rightful owner of such shares claims the shares.

XII. ALL THE REQUIREMENTS OF CORPORATE GOVERNANCE REPORT OF SUB PARAGRAPHS (2) TO (10) PARA C OF SCHEDULE V OF THE LISTING REGULATIONS HAS BEEN DULY COMPLIED WITH. All the requirements of corporate governance report of sub paragraphs (2) to (10) para C of schedule V of the listing regulations has been duly complied with except mentioned in the Annual compliance audit report and Form MR-3 if any.

XIII. ADOPTION OF DISCRETIONARY REQUIREMENTS SPECIFIED IN PART E OF SCHEDULE II OF THE LISTING REGULATIONS:

Sr No	Requirements specified in Part E of Schedule II	Adoption by the Company
1.	The Board: A non-executive chairperson may be entitled to maintain a Chairperson's office at the listed entity's expense and also allowed reimbursement of expenses incurred in performance of his duties.	The Company has an executive Chairman.
2.	Shareholder Rights: A half-yearly/quarterly declaration of financial performance including summary of the significant events in last six-months, may be sent to each household of shareholders	As the quarterly financial performance along with significant events are published in the newspapers and are also posted on the Company's website, the same are not being sent to the shareholders.
3.	Modified opinion(s) in audit report: The listed entity may move towards a regime of financial statements with unmodified audit opinion	The Company has submitted a declaration with the stock exchanges that the Statutory Auditors of the Company have issued Audit Report on Audited Financial Results for year ended 31st March, 2025 with unmodified opinion.
4.	Separate posts of Chairperson and the Managing Director or the Chief Executive Officer The listed entity may appoint separate persons to the post of the Chairperson and the Managing Director or the Chief Executive Officer, such that the Chairperson shall – (a) be a non-executive director; and (b) not be related to the Managing Director or the Chief Executive Officer as per the definition of the term "relative" defined under the Companies Act, 2013.	Separation of Chairperson and Managing Director is not mandatory as per SEBI (Listing Obligations and Disclosure Requirements) (Second Amendment) Regulations, 2022.
5.	Reporting of Internal Auditor: The Internal auditor may report directly to the Audit Committee	The Internal Auditors of the Company report directly to the Audit Committee

XIV. DETAILS OF INFORMATION ON APPOINTMENT AND RE-APPOINTMENT OF DIRECTORS FORMS PART OF THE NOTICE CONVENING THE 14TH ANNUAL GENERAL MEETING.

XV. THE DISCLOSURES OF THE COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATION 17 TO 27 AND CLAUSES (B) TO (I) OF SUB-REGULATION (2) OF REGULATION 46 OF THE LISTING REGULATIONS ARE AS FOLLOWS: All the requirements of corporate governance report of sub paragraphs (2) to (10) para C of schedule V of the listing regulations has been duly complied with except mentioned in the Annual compliance audit report and Form MR-3 if any.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN NO.: 10652494**

**DATE: 04.09.2025
PLACE: MUMBAI**

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members,
Looks Health Services Limited, 35,
Floor- 2, Plot -3/5,
Seth Lalji Dayal Building,
Dadi Seth Agiary Lane, Malharrao Wadi, Kalbadevi, Mumbai,
Maharashtra, India, 400002.

We have examined and verified the records of the Board of Directors available and maintained on the online portal of Ministry of Corporate Affairs of “**Looks Health Services Limited**” (hereinafter will known as “the Company”) having its Registered Office at **35, Floor- 2 , Plot -3/5, Seth Lalji Dayal Building, Dadi Seth Agiary Lane, Malharrao Wadi, Kalbadevi, Mumbai, Maharashtra, India, 400002** incorporated vide its Company Registration Number: L93030MH2011PLC222636 on October 01, 2011 under the jurisdiction of Registrar of Companies, Mumbai.

On the basis of examination and verification, we hereby state that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as the directors of companies by the Securities Exchange Board of India / MCA or any such statutory authority for the Financial Year ending on 31st March, 2025.

The Board of Directors of the Company comprises of 6 (Six) Directors and the Board is composed as follows:

Sr. No.	Name of the Director	DIN	Type of the Director	Status of the Director
1.	Mr. Pritesh Doshi	05155318	Executive Director, Managing Director	Active
2.	Ms. Monika Doshi	10652494	Executive Director, Chairperson	Active
3.	Mr. Mihir Ganappa	10652499	Non-Executive, Non- Independent Director	Active
4.	Ms. Sejal Jain	09092276	Non- Executive, Independent Director	Active
5.	Mr. Dhruv Rajgor	10649080	Non- Executive, Independent Director	Active
6.	Mr. Bhavin Hirpara	10649071	Non- Executive, Independent Director	Active

This Certificate is being issued at the request of the Company for the rightful compliance with Para 3(x) (c) (iii) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018

For VKM & ASSOCIATES
Company Secretaries

Sd/-
Vijay Kumar Mishra
Partner
C.P. No. 4279
Mem No. F5023
UDIN: F005023G000834368
PR: 1846/22
Place: Mumbai
Date: 22/07/2025

ANNEXURE- 3

FORM NO. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED ON 31ST MARCH, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Looks Health Services Limited,
35, Floor- 2 , Plot -3/5,
Seth Lalji Dayal Building,
Dadi Seth Agiary Lane, Malharrao Wadi,
Kalbadevi, Mumbai,
Maharashtra, India, 400002.

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by “Looks Health Services Limited” (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company’s books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of the secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2025, complied with the statutory provisions listed hereunder and the Company also has proper Board processes and compliance mechanism in place, to the extent and in the manner reported hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company at the Corporate Office at 35, Floor- 2 , Plot -3/5, Seth Lalji Dayal Building, Dadi Seth Agiary Lane, Malharrao Wadi, Kalbadevi, Mumbai- 400002, Maharashtra for the financial year ended on March 31, 2025 according to the provisions of:

1. The Companies Act, 2013 (the Act) and the rules made thereunder
2. The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made thereunder;
3. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
4. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
5. The following Regulations and Guidelines as prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act);
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **Not Applicable to the Company during the Audit period;**
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **Not Applicable to the Company during the Audit period;**
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulation, 2021- **Not Applicable to the Company during the Audit period;**
 - (e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 - **Not Applicable to the Company during the Audit period;**
 - (f) The Securities and Exchange Board of India (Registration to an Issue and Share Transfer Agents) Regulations, 1993;
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 - **Not Applicable to the Company during the Audit period;**
 - (h) The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 - **Not Applicable to the Company during the Audit period;**

We have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by The Institute of Company Secretaries of India;

- ii. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.;

Accordingly, we state that during the period under review, there were adequate systems and processes in place to monitor and ensure compliance with various applicable laws and that the Company has complied with the provisions of the Acts, Rules, Regulations, Guidelines, Standards, etc., mentioned above.

We further report that the Board of Directors of the Company is duly constituted with the proper balance of Executive Directors, Non-Executive Independent Directors. The changes in the composition of the Directors took place during the period under review were carried out in compliance with the Act.

During the period under review, the following changes in the composition of the Board took place:

1. Ms. Monika Joshi (DIN: 10652494) was appointed as a Whole Time Director of the Company for a period of 5 (Five) consecutive years w.e.f. September 05, 2024.
2. Resignation of Mr. Pritesh Doshi (DIN: 05155318) as Chairman w.e.f. September 05, 2024.
3. Appointment of Mr. Monika Joshi (DIN: 10652494) as Chairman w.e.f. September 05, 2024.
4. Appointment of Mr. Mihir Ganappa (DIN: 10652499) as Additional Director (Non-Executive) w.e.f. September 05, 2024.
5. Appointment of Mr. Dhruv Rajgor (DIN: 10649080) as Additional Director (Non-Executive) w.e.f. September 05, 2024.
6. Appointment of Mr. Bhavin Hirpara (DIN: 10649071) as Director (Non-Executive) w.e.f. September 30, 2024.
7. Resignation of Mr. Krishna Sangani (DIN: 10231157) as an Independent Director of the Company, with effect from September 30, 2024.

Adequate notice was given to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at the Board Meetings and Committee Meetings were taken with the requisite majority and are captured and recorded in the minutes of the meetings of the Board of Directors or Committees of the Board, as the case may be.

We further report that, there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that, during the audit period there were other specific events / actions in pursuance of the above referred laws, rules, regulations, guidelines, etc. having a major bearing on the Company's affairs in pursuance of the above referred laws, rules etc. as below:

1. Resignation of Company Secretary and Compliance Officer (Key Managerial Person)- Ms. Kanchan Kaku w.e.f. February 17, 2025.
2. Shifting of Registered Office within local limits to 35, Floor-2, Plot-3/5, Seth Lalji Dayal Building, Dadi Seth Agairy Lane, Malharrao Wadi, Kalbadevi, Mumbai, Maharashtra, 400002.

This report is to be read with the Annexure, which forms an integral part of this report.

**For VKM & ASSOCIATES
Company Secretaries**

**Sd/-
Vijay Kumar Mishra
Partner
C.P. No. 4279
Mem No. F5023
UDIN: F005023G00502597
PR: 1846/22
Place: Mumbai
Date: 30/05/2025**

“ANNEXURE A”

**To,
The Members,
Looks Health Services Limited,
35, Floor- 2 , Plot -3/5,
Seth Lalji Dayal Building,
Dadi Seth Agiary Lane, Malharrao Wadi,
Kalbadevi, Mumbai,
Maharashtra, India, 400002.**

Our report of even date is to be read along with this letter:

Management’s Responsibility:

1. It is the Responsibility of Management of the Company to maintain Secretarial records, device proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor’s Responsibility:

2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that the correct facts are reflected in the Secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of the financial records and books of accounts of the Company.
4. Wherever required, we have obtained the Management representation about compliance of laws, rules and regulations and happenings of events, etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, and standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.

Disclaimer

6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of efficacy or effectiveness with which the management has conducted the affairs of the Company.

**For VKM & ASSOCIATES
Company Secretaries**

**Sd/-
Vijay Kumar Mishra
Partner
C.P. No. 4279
Mem No. F5023
UDIN: F005023G00502597
PR: 1846/22
Place: Mumbai
Date: 30/05/2025**

ANNEXURE- 4

REMUNERATION POLICY FOR DIRECTORS, KMPS AND OTHER EMPLOYEES

1. INTRODUCTION:

- 1.1 Looks Health Services Limited recognise the importance of aligning the business objectives with specific and measureable individual objectives and targets. The Company has therefore formulated the remuneration policy for its directors, key managerial personnel and other employees keeping in view the following objectives:
 - 1.1.1 Ensuring that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate, to run the company successfully.
 - 1.1.2 Ensuring that relationship of remuneration to performance is clear and meets the performance benchmarks.
 - 1.1.3 Ensuring that remuneration involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the company and its goals.

2. SCOPE AND EXCLUSION:

- 2.1 This Policy sets out the guiding principles for the Nomination and Remuneration Committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the Company.

3. TERMS AND REFERENCES:

In this Policy, the following terms shall have the following meanings:

- 3.1 “Director” means a director appointed to the Board of the Company.
- 3.2 “Key Managerial Personnel” means
 - (i) the Chief Executive Officer or the Managing Director or the Manager;
 - (ii) the Company Secretary;
 - (iii) the Whole-time Director;
 - (iv) the Chief Financial Officer; and
 - (v) such other officer as may be prescribed under the Companies Act, 2013.
- 3.3 “Nomination and Remuneration Committee” means the committee constituted by Looks Health Services Limited’s Board in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

4. POLICY:

- 4.1 Remuneration to Executive Directors and Key Managerial Personnel
 - 4.1.1 The Board, on the recommendation of the Nomination and Remuneration (NRC) Committee, shall review and approve the remuneration payable to the Executive Directors of the Company within the overall limits approved by the shareholders.
 - 4.1.2 The Board, on the recommendation of the NRC Committee, shall also review and approve the remuneration payable to the Key Managerial Personnel of the Company.
 - 4.1.3 The remuneration structure to the Executive Directors and Key Managerial Personnel may include (i) Basic Pay (ii) Perquisites and Allowances. (iii) Commission or (iv) bonus etc.
- 4.2 Remuneration to Non-Executive Directors
 - 4.2.1 The Board, on the recommendation of the NRC Committee, shall review and approve the remuneration payable to the Non-Executive Directors of the Company within the overall limits approved by the shareholders.
 - 4.2.2 Non-Executive Directors shall be entitled to sitting fees for attending the meetings of the Board and the Committees thereof.
- 4.3 Remuneration to other employees
 - 4.3.1 Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile, skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

5. AMENDMENT

The Board of Directors on its own and / or as per the recommendations of Nomination and Remuneration Committee can amend this Policy, as and when deemed fit.

In case of any subsequent amendment/modification in the Listing Regulations, the Companies Act, 2013 and/or other applicable laws in this regard shall automatically apply to this Policy.

ANNEXURE- 5

DIRECTORS'/ EMPLOYEES REMUNERATION

[Pursuant to Section 197(12) of Companies Act, 2013 read with Rule 5 of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

Ratio of the remuneration of each Director to the median remuneration of the employees and the percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary in the financial year 2024-25 and the comparison of the remuneration of the Key Managerial Personnel against the performance of the Company is as follows:

PARTICULARS OF EMPLOYEES

The information required under Section 197 of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

- A) The ratio of the remuneration of each director to the median remuneration of the employees of the Company for the financial year*:2024-25 ;

Sr. no.	Name of the Director/KMP	Ratio of remuneration to the median remuneration of the employees
1	Mr. Pritesh Champalal Doshi- MD	0.17
2	Ms. Kanchan Kaku- CS	1.53
3	Mr. Milinath Gavas- CFO	0.44

- B) The percentage increase in remuneration of each director, chief executive officer, chief financial officer, company secretary in the financial year 2024-25;

Sr. no.	Name of the Director/KMP	% increase in remuneration in the financial year 2024-25 compared to 2023-24
1	Mr. Pritesh Champalal Doshi- MD	0.00
2	Ms. Kanchan Kaku- CS	8.13
3	Mr. Milinath Gavas- CFO	0.00

- C) The percentage increase in the median remuneration of employees in the financial year:
There is increase of 8.13 % in the median remuneration of employees in the financial year 2024-25 as compared to previous year 2023-24.
- D) The number of permanent employees on the rolls of Company: 06
- E) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:
Average percentile decrease made in the salaries of employees other than the managerial personnel in the last financial year is 40.74% and percentile decrease in the managerial remuneration is 5.67 %.
- F) Affirmation that the remuneration is as per the remuneration policy of the Company: The Company affirms remuneration is as per the remuneration policy of the Company.

ANNEXURE- 6

CFO/MD CERTIFICATION

To
The Board of Directors,
Looks Health Services Limited,

We, undersigned, in our respective capacities in **Looks Health Services Limited** hereby certify that:

1. We have reviewed Financial Statements and the Cash Flow Statement for the Financial Year ended March 31, 2025 and that to the best of our knowledge and belief:
 - a) These statements do not contain any materially untrue statement or omit any material fact or contain statement that might be misleading;
 - b) These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
2. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
3. We are responsible for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
4. We have indicated to the Auditors and the Audit committee that;
 - a) There have been no significant changes in internal control over financial reporting during the year;
 - b) There have been no significant changes in accounting policies during the year; and
 - c) There have been no instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

SD/-
PRITESH CHAMPALAL DOSHI
MANAGING DIRECTOR
(DIN: 05155318)

SD/-
MILINATH GAVAS
CHIEF FINANCIAL OFFICER

PLACE: MUMBAI
DATED: 04.09.2025

ANNEXURE- 7

DECLARATION ON CODE OF CONDUCT

To the best of my knowledge and belief and on the basis of declarations given to me by the Directors and the Senior Management Personnel of the Company, I hereby affirm that a Code of Conduct for the Board Members and the Senior Management Personnel of the Company which includes Code of Conduct for Prevention of Insider Trading and Whistle Blower Policy has been approved by the Board of Directors and all Directors and the Senior Management Personnel have fully complied with the provisions of the Code of Conduct of the Company.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
LOOKS HEALTH SERVICES LIMITED**

**SD/-
MONIKA JOSHI
WHOLE TIME DIRECTOR
DIN NO.: 10652494**

**DATE: 04.09.2025
PLACE: MUMBAI**

ANNEXURE- 8

CERTIFICATE REGARDING COMPLIANCE WITH THE CONDITIONS OF CORPORATE GOVERNANCE TO THE MEMBERS OF LOOKS HEALTH SERVICES LIMITED

We have examined the compliance of the conditions of Corporate Governance procedures implemented by LOOKS HEALTH SERVICES LIMITED for the year ended on March 31, 2025, as per the relevant provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'):

The Compliance of the conditions of Corporate Governance is the responsibility of the Management. This responsibility includes the design, implementation and maintenance of internal control and procedures to ensure the compliance with the conditions of the Corporate Governance stipulated in Listing Regulations.

Our examination has been limited to a review of the procedures and implementations thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion of the financial statements of the Company.

In our opinion and to the best of our information and according to our examination of the relevant records and the explanations given to us and the representations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in above-mentioned Listing Agreement/ Listing Regulation, as applicable.

As on March 31, 2025 there were no valid investor grievance matters against the Company remaining unattended / pending for more than 30 days.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For VKM & Associates
Practicing Company Secretaries**

**Sd/-
Vijay Kumar Mishra
Partner
M. No. F-5023
C.P. No.4279
UDIN: F005023G000937141**

**Place: Mumbai
Date: 05/08/2025**

INDEPENDENT AUDITOR'S REPORT

To,
The Members of,
LOOKS HEALTH SERVICES LIMITED
(CIN: L93030MH2011PLC222636)

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of LOOKS HEALTH SERVICES LIMITED ("the Company"), which comprise the balance sheet as at March 31, 2025, the statement of Profit and Loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("The Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matters: Expected credit loss allowances Recognition and measurement of impairment of financial assets involve significant management judgement. With the applicability of Ind AS 109, credit loss assessment is now based on expected credit loss (ECL) model. The Company's impairment allowance is derived from estimates including the historical default and loss ratios. Management exercises judgement in determining the quantum of loss based on a range of factors. The most significant areas are loan staging criteria, calculation of probability of default / loss and consideration of probability weighted scenarios and forward-looking macroeconomic factors. There is a large increase in the data inputs required by the ECL model. This increases the risk of completeness and accuracy of the data that has been used to create assumptions in the model. In some cases, data is unavailable and reasonable alternatives have been applied to allow calculations to be performed. As per management opinion, there is no expected credit loss in several financial assets including the trade receivables and other financial assets of the Company and all are on fair value, based on the assessment and judgement made by the board of the company.	How the matter was addressed in our Audit In view of the significance of the matter we applied the following audit procedures, on test check basis, in this area, among others to obtain reasonable audit assurance: - We evaluated management's process and tested key controls around the determination of extent of requirement of expected credit loss allowances, including recovery process & controls implemented in the company for trade receivables and other financial assets. It was explained to us by the management that the control exists relating to the recovery of receivables, including those aging for large periods and in the opinion of the board there is no requirement making expected credit loss allowance. - We have also reviewed the management response and representation on recovery process initiated for sample receivables, and based on the same we have placed reliance on these key controls for the purposes of our audit.
Appropriateness of Current and Non-Current Classification	For the purpose of current & non-current classification the Company has considered its normal operating cycle as 12 Months and the same is based on services provided, acquisition of assets or inventory, their realization in cash and cash equivalents. The classification is either done on basis of documentary evidence and if not then on the basis of

	managements best estimate of period in which asset would be realized or liability would be settled.
Revenue Recognition The principal business of the company is providing dental and other cosmetic/non- cosmetic services & sale of supporting medicine. Revenue from services is recognized upon rendering of service & receipt of payment at clinic. Revenue from sale is recognized upon transfer of significant risk and reward & transfer of control of goods to customers. We identified revenue recognition as a key audit matter because there is a risk of revenue considering the judgments involved in the revenue recognition for services.	In view of the significance of the matter we applied the following audit procedures, on test check basis, in this area, among others to obtain reasonable audit assurance: Assessed the appropriateness of the revenue recognition accounting policies, by comparing with applicable accounting standards. Evaluated the design of controls and operating effectiveness of the relevant controls with respect to revenue recognition and accounting for services/sales. Performed substantive testing by selecting samples of revenue transactions recorded during the year by verifying the underlying documents. Carried out analytical procedures on revenue recognized during the year to identify unusual variances. Performed confirmation procedures on trade receivable balances at the balance sheet date on a sample basis. Tested, on a sample basis, specific revenue transactions recorded before and after the financial year end date to determine whether the revenue had been recognised in the appropriate financial period.

Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

The Director's report is not made available to us at the date of this auditor's report. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a

basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in
 - (i) Planning the scope of our audit work and in evaluating the results of our work; and
 - (ii) To evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure "A" statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;
- (e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B";
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. Except disputed tax liabilities mentioned in Annexure A point (vii) (c), the Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses, and

- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
 - a) The management has represented that, to the best of its knowledge and belief that, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b) The management has represented, that, to the best of its knowledge and belief that, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.
- v. No dividend has been declared or paid during the year by the Company.
- vi. Based on our examination which included test checks, the company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For KPSJ&ASSOCIATES LLP
(Chartered Accountants)
FRN: 124845W/W100209

Sd/-
PRAKASHCHANDRA PARAKH
(Partner)
M.NO: 039946
UDIN: 25039946BMIFA06391
Place: Ahmedabad
Date: 26/05/2025

Annexure "A" to the Independent Auditor's Report (Continued)

(Referred to paragraph under 'Report on other legal and regulatory requirements' section of the Independent Auditors' Report of even date to the members of LOOKS HEALTH SERVICES LIMITED on the financial statements for the year ended March 31, 2025)

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

i.	In respect of the Company's Property, Plant & Equipment and Intangible assets: (a) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment and relevant details of right-of-use. (B) The company has no intangible assets present for the period under review; (b) The company has a regular programme for physical verification in a phased periodic manner, which, in our opinion, is reasonable having regards to the size of the company and the nature of its assets. No material discrepancies were noticed on such verifications. (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company does not own any immovable property (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee). Accordingly, reporting under clause 3(i)(c) of the Order is not applicable to the Company. (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not re-valued its Property, plant and equipment (including Right-of-use assets). (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any Benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made there-under. Accordingly, reporting under clause 3(i)(e) of the Order is not applicable to the Company.
ii.	(a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company does not hold any inventory during the year. Accordingly, reporting under clause 3(ii)(a) of the Order are not applicable. (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned a working capital limit in excess of Rs 5 crore by bank or financial institution based on the security of current assets during the year. Accordingly, reporting under clause 3(ii)(b) of the Order are not applicable.
iii.	According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made investments in the equity shares of the companies and company has not provided any guarantee or security to companies, firms, limited liability partnerships or any other parties during the year. The Company has not granted loans whether secured or unsecured to companies, firms, limited liability partnerships or any other parties during the year. However the Company has granted advances to companies, firms, and other parties during the year, which, though classified as trade advances, are in the nature of financial accommodation. The details of such loans are stated in sub-clause (a) below: (a) A. Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has not granted any loans to subsidiaries. B. Based on the audit procedures carried on by us and as per the information and explanations given to us, The Company has not granted loans (in the form of advances) to parties other than subsidiaries, which are not supported by underlying transactions for goods or services and are therefore considered to be in the nature of loans. These are disclosed in the financial statements. (b) According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the terms and conditions of the loans given are, prima facie prejudicial to the interest of the Company, as the loans were granted without charging interest and without proper documentation or defined repayment terms. (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, the repayment of principal and payment of interest has not been stipulated and the repayments or receipts have been irregular. (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given. (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan given falling due during the year, which has been renewed or extended or fresh loans given to settle the overdue of existing loans given to the same party. (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not given loans repayable on demand which was without specifying any terms or period of repayment.

iv.	In our opinion and according to information and explanation given to us, in respect of loans, investments, guarantees and security, the Company has complied with the provisions of sections 185 and section 186 of the Companies Act, 2013.																				
v.	In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits or there is no amount which has been considered as deemed deposit within the meaning of sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, reporting under clause 3(v) of the Order is not applicable to the Company.																				
vi.	In our opinion and according to information and explanation given to us, the provisions of section 148 of the companies act, 2013 is not applicable to the company for the period under review, accordingly paragraph 3 (vi) of the order is not applicable.																				
vii.	In respect of statutory dues: (a) In our opinion, and according to the information and explanations given to us, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, have generally been regularly deposited with the appropriate authorities by the Company, though there have been slight delays in a few cases. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable. (b) According to the information and explanations given to us, there are no statutory dues referred to in subclause (a) above that have not been deposited with the appropriate authorities on account of any dispute, except those disclosed below: <table><tr><td>Name of the statute</td><td>Nature of the dues</td><td>Amount (Rs)</td><td>Period to which the amount relates</td><td>Forum where the dispute is pending</td></tr><tr><td>Maharashtra VAT</td><td>Maharashtra VAT</td><td>3,74,999/-</td><td>FY 2013-2014</td><td>Maharashtra Sales Tax Tribunal (Amount paid under Dispute Rs 374,999)</td></tr><tr><td>Service Tax</td><td>Service Tax</td><td>8,63,612/-</td><td>FY 2014-2015</td><td>Central Excise & Service Tax Appellate Tribunal (Amount paid under Dispute Rs 86,500)</td></tr><tr><td>Income Tax</td><td>Accrued Interest</td><td>45,720/-</td><td>FY 2017-2018</td><td>Income Tax</td></tr></table>	Name of the statute	Nature of the dues	Amount (Rs)	Period to which the amount relates	Forum where the dispute is pending	Maharashtra VAT	Maharashtra VAT	3,74,999/-	FY 2013-2014	Maharashtra Sales Tax Tribunal (Amount paid under Dispute Rs 374,999)	Service Tax	Service Tax	8,63,612/-	FY 2014-2015	Central Excise & Service Tax Appellate Tribunal (Amount paid under Dispute Rs 86,500)	Income Tax	Accrued Interest	45,720/-	FY 2017-2018	Income Tax
Name of the statute	Nature of the dues	Amount (Rs)	Period to which the amount relates	Forum where the dispute is pending																	
Maharashtra VAT	Maharashtra VAT	3,74,999/-	FY 2013-2014	Maharashtra Sales Tax Tribunal (Amount paid under Dispute Rs 374,999)																	
Service Tax	Service Tax	8,63,612/-	FY 2014-2015	Central Excise & Service Tax Appellate Tribunal (Amount paid under Dispute Rs 86,500)																	
Income Tax	Accrued Interest	45,720/-	FY 2017-2018	Income Tax																	
viii.	According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.																				
ix.	According to information and explanation given to us, (a) The company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender. (b) The company has not been declared wilful defaulter by any bank or financial institution or other lender; (c) The company has not accepted term loans for the period under review. (d) The company has not raised funds on short term basis which have been utilized for long term purposes. (e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures. (f) The company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.																				
x.	(a) The company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the order is not applicable. (b) The company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year and hence reporting under clause 3(x)(b) of the order is not applicable.																				
xi.	(a) According to the information available with us, no fraud by the company and no fraud on the company has been noticed or reported during the year. (b) According to the information available with us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government; during the year and up to the date of this report. (c) As represented to us by the management, there were no whistle-blower complaints received during the year and hence reporting under clause 3(xi)(c) of the order is not applicable.																				
xii.	The Company is not a Nidhi Company has complied and hence reporting under clause (xii) of the order is not applicable.																				
xiii.	In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Sections 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable Indian Accounting Standards. However, the company has not filed E-Form MGT-14 with Registrar of Companies for approval of related parties' transactions.																				
xiv.	(a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business; (b) We have considered the internal audit reports of the Company issued till date for the period under audit.																				

xvi.	(a) According to the information given to us, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934). Hence reporting under this clause not applicable to the company. (b) According to the information given to us, the company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Hence reporting under this clause not applicable to the company. (c) According to the information given to us, the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Hence reporting under this clause not applicable to the company. (d) According to the information given to us, there is no Core Investment Company (CIC) within the Group (as defined in the core investment companies (Reserve Bank of India) Directions, 2016) and accordingly reporting under this clause not applicable to the company.
xvii.	According to the information given to us, the Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
xviii.	There has been change in statutory auditor during the year and there were no issues, objections and concerns raised from the previous auditor.
xix.	On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the board of directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention which causes us to believe that any material uncertainty exists as on the date of the audit report that indicating that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however state that our reporting is based on the facts up to the date of audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
xx.	According to the information and explanations given to us, the Company does not fulfil the criteria as specified under section 135(1) of the Act read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 and according, reporting under clause 3(xx) of the Order is not applicable to the Company.
xxi.	The company is not required to prepare Consolidated financial statements under Section 129 of Companies Act, 2013.

For: KPSJ&ASSOCIATES LLP
(Chartered Accountants)
FRN: 124845W/W100209

Sd/-
PRAKASHCHANDRA PARAKH
(Partner)
M.NO: 039946
UDIN: 25039946BMIFAO6391
Place: Ahmedabad
Date: 26/05/2025

LOOKS HEALTH SERVICES LIMITED BALANCE SHEET AS AT 31ST MARCH, 2025
(Currency: Indian Rupees in Lakhs)

Particulars	Notes	As At March 31, 2025	As At March 31, 2024
ASSETS			
Non-current assets			
Property Plant and Equipment	2	35.85	50.01
Financial assets			
- Loans	3	-	784.00
Non-Current Tax Assets (Net)		-	-
Other Non-Current Assets	4	1,380.00	630.00
Total Non Current Assets		1,415.85	1,464.01
Current assets			
Financial assets			
- Trade Receivables	5	39.47	-
- Cash and cash equivalents	6	30.61	8.15
Current Tax Assets (Net)	7	1.16	3.13
Other Current Asset	8	7.74	9.24
Total Current Assets		78.97	20.53
Total Assets		1,494.82	1,484.54
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	9	1,050.00	1,050.00
Other equity	10	432.53	430.14
Total Equity		1,482.53	1,480.14
Non-current liabilities -			
Financial liabilities			
- Other financial Liabilities		-	-
Deferred tax Liabilities (Net)	11	1.52	3.77
Total Non Current Liabilities		1.52	3.77
Current liabilities -			
Financial liabilities			
- Other financial liabilities	12	-	0.32
Other current liabilities	13	10.77	0.32
Current Tax Liabilities (Net)		-	-
Total Current Liabilities		10.77	0.63
TOTAL Liabilities		1,494.82	1,484.54

Significant Accounting Policies

01

See accompanying notes to the financial statements

02-62

As per our Report of even date

For KPSJ & Associates LLP

For and on behalf of the Board

Chartered Accountants

Looks Health Services Limited

(Firm Reg. No. 124845W/W100209)

Prakashchandra Parakh

(Partner) M.No. 039946

UDIN: 25039946BMIFAO6391

Place : Ahmedabad Date :

26/05/2025

Pritesh Champalal Doshi

(Managing Director)

DIN: 05155318
Monika Joshi

(WTD)

DIN: 10652494
Vandanaben Ajeshkumar
Sheladiya

(Company Secretary)

ICSI Member No: A45323
Milnath Gavas

(CFO)

LOOKS HEALTH SERVICES LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH 2025

(Currency: Indian Rupees in Lakhs)

Particulars	Notes	Year Ended on Mar 31, 2025	Year Ended on Mar 31, 2024
INCOME			
Revenue From Operations	14	39.47	-
Other Income	15	39.05	45.76
Total Income		78.52	45.76
EXPENSES			
Purchase of Stock-in-Trade		-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade		-	-
Employee benefit expense	16	33.66	27.13
Finance Cost	17	0.00	0.00
Depreciation and amortization Expenses	2	14.17	14.17
Other Expenses	18	27.80	6.83
Total Expenses		75.64	48.12
PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX		2.89	(2.36)
Less: Exceptional Item			
Prior period Exp		-	-
PROFIT BEFORE TAX		2.89	(2.36)
Tax Expenses -			
Current Tax		2.74	1.42
Deferred tax	10	(2.24)	(2.01)
Prior year tax adjustments (net)		-	-
Total Tax Expenses		0.50	(0.59)
Profit for the Year (After Tax)		2.39	(1.77)
Other Comprehensive Income		-	-
Total Comprehensive Income for the year		2.39	(1.77)
Earnings Per equity share of face value of Rs 10 each	40		
Basic(in Rs)		0.02	(0.02)
Diluted (in Rs)		0.02	(0.02)

Significant Accounting Policies

See accompanying notes to the financial statements

As per our Report of even date

For KPSJ & Associates LLP

Chartered Accountants

(Firm Reg. No. 124845W/W100209)

01

02-62

For and on behalf of the Board

Looks Health Services Limited

Prakashchandra Parakh

(Partner) M.No. 039946

UDIN: 25039946BMIFA06391

Place : Ahmedabad Date :

26/05/2025

Pritesh Champalal Doshi

(Managing Director)

DIN: 05155318

Monika Joshi

(WTD)

DIN: 10652494

Vandanaben Ajeshkumar

Sheladiya

(Company Secretary)

ICSI Member No:

Place : Ahmedabad

Milinandh Gavas

(CFO)

LOOKS HEALTH SERVICES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025

(Currency: Indian Rupees in Lakhs)

Particulars		Current Year 2024-25	Current Year 2023-24
Cash flow from/(used in) operating activities			
Profit before tax		2.89	(2.36)
Adjustment for:			
Interest income on deposits and dividend income		(38.95)	(45.52)
Depreciation and amortization		14.17	14.17
(Profit)/Loss from sale of Property, plant and equipment		-	-
Operating profit before working capital changes		(21.90)	(33.72)
Movement in working capital:			
(Increase)/decrease in Trade Receivables		(39.47)	-
(Increase)/decrease in other Current Assets		1.51	(1.32)
Increase/(decrease) in trade payables		-	(0.06)
Increase/(decrease) in other liability		(0.32)	-
Increase/(decrease) in provision		10.45	0.26
Cash generated/(used) in operations		(49.73)	(34.84)
Income taxes paid		0.76	0.07
Net Cash flow from operating activities	(A)	(50.49)	(34.91)
Cash flow from/(used) investing activities -			
Interest received		38.95	45.52
(Increase)/decrease in Trade Advances		(750.00)	-
(Increase)/decrease in Loans & Advances		784.00	(19.00)
Cash generated/(used) in investing activities	(B)	72.95	26.52
Cash flow from/(used in) financing activities -			
Increase/(decrease) in other financial liability		-	-
Cash generated/(used) in financing activities	(C)	-	-
Net increase/(decrease) in cash and cash equivalents	(A+B+C)	22.46	(8.39)
Cash and cash equivalent at beginning of year		8.15	16.54
Unrealised exchange difference		-	-
Total Cash and cash equivalent at beginning of year		8.15	16.54
Cash and cash equivalent at end of year		30.61	8.15
Unrealised exchange difference at year end		-	-
Total Cash and cash equivalent at end of year		30.61	8.15

Note- Cash Flow Statement has been prepared under the indirect method as set out in IND AS 7 - "Cash Flow Statements" prescribed under the Companies Act (Indian Accounting Standard) Rules, 2015 under the Companies Act, 2013

As per our Report of even date

For KPSJ & Associates LLP

Chartered Accountants

(Firm Reg. No. 124845W/W100209)

Prakashchandra Parakh

(Partner) M.No. 039946

UDIN: 25039946BMIFA06391

Place : Ahmedabad Date :

26/05/2025

For and on behalf of the Board

Looks Health Services Limited

Pritesh Champalal Doshi

(Managing Director)

DIN: 05155318

Monika Joshi

(WTD)

DIN: 10652494

Vandanaben Ajeshkumar

Sheladiya

(Company Secretary)

ICSI Member No: A45323

Place : Ahmedabad

Milnath Gavas

(CFO)

LOOKS HEALTH SERVICES LIMITED**Statement of Changes in Equity as on 31st March 2025**

(Currency: Indian Rupees in Lakhs)

(a) Equity share capital	As at 31 March 2025		As at 31 March 2024	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting period Balance	1,05,00,000	1,050.00	1,05,00,000	1,050.00
Changes in equity share capital during the year	-	-	-	-
Balance at the end of the reporting period	1,05,00,000	1,050.00	1,05,00,000	1,050.00

(b) Other equity

Particulars	Reserves & Surplus		Total
	Securities Premium Account	Retained Earnings	
Balance at 31 March 2023	450.00	(18.09)	431.91
Profit for the year	-	(1.77)	(1.77)
Other comprehensive income for the year	-	-	-
Other adjustments - Lease Asset adjustments	-	-	-
Total Comprehensive Income for the year	-	(1.77)	(1.77)
Balance at 31 March 2024	450.00	(19.86)	430.14
Balance at 1 April 2024	450.00	(19.86)	430.14
Profit for the year	-	2.39	2.39
Other comprehensive income for the year	-	-	-
Total comprehensive income for the year	-	2.39	2.39

As per our Report of even date

For KPSJ & Associates LLP

Chartered Accountants

(Firm Reg. No. 124845W/W100209)

For and on behalf of the Board**Looks Health Services Limited****Prakashchandra Parakh**

(Partner)

M.No. 039946

UDIN: 25039946BMIFAO6391

Place : Ahmedabad

Date : 26/05/2025

Pritesh Champalal Doshi

(Managing Director)

DIN: 05155318**Monika Joshi**

(WTD)

DIN: 10652494**Vandanaben Ajeshkumar Sheladiya**

(Company Secretary)

Milínath Gavas

(CFO)

ICSI Member No: A45323

Place : Ahmedabad

Looks Health Service Limited

Notes to financial statements as on 31st March 2025

Note 1 Significant accounting policies

1 Basis of preparation of financial statements

The financial statements are prepared in accordance with Ind AS notified under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.

The financial statement of the Company for year ended March 31, 2025 were authorised for issue in accordance with a resolution of the Board of Directors.

Basis of measurement

The financial statements have been prepared on the historical cost basis except for the following -

- Certain financial assets and liabilities (Shares, Derivative instruments etc) that are measured at fair value
- Share based payments

2 Functional and presentation currency

Items included in the financial statements of Company are measured using the currency of the primary economic environment in which the Company operates ("the functional currency"). Indian rupee is the functional currency of the Company.

3 Use of estimates

The preparation of financial statements in conformity of Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, the disclosures of contingent assets and contingent liabilities at the date of financial statements, income and expenses during the period. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in future periods which are affected.

Application of accounting policies that require critical accounting estimates and assumption having the most significant effect on the amounts recognised in the financial statements are:

Valuation of financial instruments

Valuation of derivative financial instruments

Useful life of property, plant and equipment

Useful life of investment property

Provisions

Recoverability of trade receivables

Summary of significant accounting policies -

4 Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents.

The Company has identified twelve months as its operating cycle.

4.01 Fair value measurement

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 - Quoted (unadjusted) market prices in active markets for specific or identical assets or liabilities
- Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for distribution in discontinued operations.

At each reporting date, the Management analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the Company's accounting policies. For this analysis, the Management verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents.

The Management also compares the change in the fair value of each asset and liability with relevant external sources to determine whether the change is reasonable.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

This note summarises accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

Disclosures for valuation methods, significant estimates and assumptions.

Financial instruments (including those carried at amortised cost).

4.02 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

Interest and dividend income -

The interest and dividends are recognised only when no uncertainty as to measurability or collectability exists. Interest on fixed deposits is recognised on time proportion basis taking into account the amount outstanding and the rate applicable.

4.03 Inventories

Inventory comprise of Shares and Cost of shares includes cost of purchase & other direct broker costs incurred in purchasing Shares. Inventories are valued at the lower of cost and the fair market value.

4.04 Foreign currency transactions and translation

- i) Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated in functional currency at closing rates of exchange at the reporting date.
- ii) Exchange differences arising on settlement or translation of monetary items recognised in statement of profit and loss.

4.05 Taxes

Current income tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The Company determines the tax as per the provisions of Income Tax Act 1961 and other rules specified thereunder.

Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

4.06 Deferred tax

Deferred tax is provided in full using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised, except when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity .

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

4.07 a) Property, plant and equipment

Property, plant and equipment is stated at cost less accumulated depreciation and where applicable accumulated impairment losses. Property, plant and equipment and capital work in progress cost include expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials, direct labour and any other costs directly attributable to bringing the asset to a working condition for its intended use and the costs of dismantling and removing the items and restoring the site on which they are located. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Subsequent Cost

The cost of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part is de-recognised and charged to the statement of Profit and Loss. The costs of the day-to-day servicing of property, plant and equipment are recognised in the Statement of Profit and Loss.

b) Intangible assets

Intangible assets are stated at cost less accumulated amortisation and impairment loss. The system software which is expected to provide future enduring benefits is capitalised. The capitalised cost includes license fees and cost of implementation/system integration.

Depreciation and amortisation

The depreciation on tangible assets is provided at the rates and in manner prescribed under Part C of Schedule II to the Companies Act 2013.

The company Follow SLM Method of Depreciation

Computer software is amortised over a period of 5 years.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each

financial year end and adjusted prospectively, if appropriate.

Derecognition of assets

An item of property plant & equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset is included in the income statement when the asset is derecognised.

4.08 Investment property

Property that is held for long term rental yield or for capital appreciation or both, and that is not occupied by the Company, is classified as Investment property. Investment properties measured initially at cost including related transitions cost and where applicable borrowing cost. Subsequent expenditure is capitalised to the assets carrying amount only when it is probable that future economic benefits associated with the expenditure will flow to the entity and the cost of the item can be measured reliably. All other repairs and maintainance costs are expensed when incurred. When part of an investment property is incurred the carrying amount of replaced part is derecognised.

Investment properties other than land are depreciated using SLM method over the estimated useful life of assets prescribed by the Schedule II to the Companies Act 2013 i.e. 60 years for office premises. Investment properties include:

(i)Office premises.

4.09 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

4.10 Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognised because it cannot be measured reliably. The contingent liability is not recognised in books of account but its existence is disclosed in financial statements.

4.11 Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use.

Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

4.12 Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually

certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

4.13 Financial instruments

Initial recognition

The company recognise the financial asset and financial liabilities when it becomes a party to the contractual provisions of the instruments. All the financial assets and financial liabilities are recognised at fair value on initial recognition, except for trade receivable which are initially recognised at transaction price. Transaction cost that are directly attributable to the acquisition of financial asset and financial liabilities, that are not at fair value through profit and loss, are added to the fair value on the initial recognition.

Subsequent measurement

(A) Non derivative financial instruments

(i) Financial Assets at amortised cost

A financial assets is measured at the amortised cost if both the following conditions are met :

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

This category is the most relevant to the Company. All the Loans and other receivables under financial assets (except Investments) are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Trade receivables do not carry any interest and are stated at their nominal value as reduced by impairment amount.

(ii) Financial Assets at Fair Value through Profit or Loss/Other comprehensive income

Instruments included within the FVTPL category are measured at fair value with all changes recognised in the Statement of Profit and Loss.

If the company decides to classify an instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognised in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the company may transfer the cumulative gain or loss within equity.

(iii) Financial liabilities

The measurement of financial liabilities depends on their classification, as described below:

(a) Loans and borrowings

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest rate (EIR) method. However, the Company has borrowings at floating rates. Considering the impact of restatement of Effective interest rate, transaction cost is being amortised over the tenure of loan and borrowing.

(b) Trade & other payables

After initial recognition, trade and other payables maturing within one year from the Balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

4.14 Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, as they are considered an integral part of the Company's cash management.

4.15 Earnings per share

Basic earnings per share is computed by dividing the net profit attributable to equity shareholders for the year, by the weighted average number of equity shares outstanding during the year, adjusted for bonus element in equity shares issued during the year.

Diluted earnings per share is computed by dividing the net profit attributable to equity shareholders for the year, by the weighted average number of equity shares outstanding during the year after giving effect to all dilutive potential equity shares.

5 New Accounting Standard -

Leases (Ind AS 116) -

Ind AS 116 is applicable for financial reporting periods beginning on or after 1 April 2019 and replaces existing lease accounting guidance, namely Ind AS 17. Ind AS 116 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognises a right-of-use ("ROU") asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. The nature of expenses related to those leases will change as Ind AS 116 replaces the operating lease expense (i.e., rent) with depreciation charge for ROU assets and interest expense on lease liabilities. There are recognition exemptions for short-term leases and leases of low-value items.

Lessor accounting remains similar to the current standard – i.e. lessors continue to classify leases as finance or operating leases. The Company is in the process of analysing the impact of new lease standard on its financial statements.

LOOKS HEALTH SERVICES LIMITED
Notes to financial statements as on 31st March 2025
(Currency: Indian Rupees in Lakhs)
Note 2
Property, Plant and Equipment

Particulars	Property, Plant and Equipment						Right to Use (Leased Office Premise)	Total
	AC	Furniture and fixtures	Medical Equipment	Computer & Accessories	Electrical Equipment	Vehicle		
Gross Block (At cost)								
As at 31 March 2023	-	-	148.72	-	-	0.10	-	148.82
Additions	-	-	-	-	-	-	-	-
Deduction / Adjustment	-	-	-	-	-	-	-	-
As at 31 March 2024	-	-	148.72	-	-	0.10	-	148.82
Additions	-	-	-	-	-	-	-	-
Deduction / Adjustment	-	-	-	-	-	-	-	-
As at 31 March 2025	-	-	148.72	-	-	0.10	-	148.82
Depreciation/amortisation								
As at 31 March 2023	-	-	84.54	-	-	0.10	-	84.64
For the year	-	-	14.17	-	-	-	-	14.17
Deductions/Adjustments	-	-	-	-	-	-	-	-
As at 31 March 2024	-	-	98.70	-	-	0.10	-	98.80
For the year	-	-	14.17	-	-	-	-	14.17
Deductions/Adjustments	-	-	-	-	-	-	-	-
As at 31 March 2025	-	-	112.87	-	-	0.10	-	112.97
Net Block								
At 31 March 2023	-	-	64.18	-	-	-	-	64.18
At 31 March 2024	-	-	50.01	-	-	-	-	50.01
At 31 March 2025	-	-	35.85	-	-	-	-	35.85

LOOKS HEALTH SERVICES LIMITED**Notes to financial statements as on 31st March 2025***(Currency: Indian Rupees in Lakhs)*

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 3		
Loans		
Unsecured considered good unless stated otherwise :	-	784.00
Loans Given to Non-Corporate Entities (Unsecured)		
Total	-	784.00
Subnote:		
- The status of balance and transaction confirmations of Loans are disclosed in Note 37		

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 4		
Other Non-Financial Assets		
a. Trade Advance	1,380.00	630.00
Trade Advances for Supply of Goods/ Assets		
Total	1,380.00	630.00
Subnote:		
- The status of balance and transaction confirmations of Advances are disclosed in Note 37		

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 5		
Trade Receivables		
Trade Receivables from Stock Broking Activities		
-considered good, outstanding for more then six month	-	-
-considered good, outstanding for less then six month	39.47	-
Total	39.47	-

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 6		
Cash and cash equivalents		
Cash on Hand	0.41	0.43
Balance with Bank	30.20	7.72

Total	30.61	8.15
Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 7		
Current Tax Assets (Net)		
Income Tax refund due for current year / TDS Receivable	3.90	4.55
Less:		
Income Tax Provision	2.74	1.42
Total	1.16	3.13

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 8		
Other Current Asset		
Prepaid Expenses	0.06	0.08
Salary Payable (Dr. Bal)	-	0.25
Advance To Creditor for Expenses (Dr. Bal)	0.50	-
Audit Fees Payable (Dr. Bal)	0.30	-
Balance With Revenue Authorities		
GST Credit	5.92	4.29
Deposit against Appeal (MVAT)	-	3.75
Service Tax Paid - For Appeal	0.87	0.87
TDS Payable (Dr. Bal)	0.09	-
Total	7.74	9.24

LOOKS HEALTH SERVICES LIMITED
Notes to financial statements as on 31st March 2025
(Currency: Indian Rupees in Lakhs)

	Particulars	As at 31st March' 2025	As at 31st March' 2024
	Note: 9		
	Share Capital		
a	Authorised :		
	Equity Shares of Re. 10/- each		
	120,00,000 (PY 120,00,000) Equity Shares of Rs.10/- Each	1,200.00	1,200.00
	TOTAL	1,200.00	1,200.00
b	Issued and Subscribed and Paid up:		
	105,00,000 (Previous year 105,00,000) Equity shares fully paid up	1,050.00	1,050.00
	TOTAL	1,050.00	1,050.00
c	Reconciliation of number of shares outstanding at the beginning and end of the year :		
	Equity share :		
	Outstanding at the beginning of the year	1,05,00,000	1,05,00,000
	Add/(Less) : Adjustments during the year	-	-
	Equity shares allotted as fully paid bonus shares by capitalisation of reserves	-	-
	Equity Shares bought back during the year	-	-
	Outstanding at the end of the year	1,05,00,000	1,05,00,000

d Terms / Rights attached to each classes of shares Terms / Rights attached to Equity shares

The Company has only one class of equity shares with voting rights having a par value of Re 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders at the ensuing Annual General Meeting, except in case of interim dividend.

During the year ended 31 March 2025, the amount of dividend per equity share recognised as distributions to equity shareholders is NIL (previous year NIL).

In the event of liquidation of the Company, the shareholders of equity shares will be entitled to receive remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

e Shareholders holding more than 5% shares in the company is set out below:

Equity share	As at 31st March' 2025		As at 31st March' 2024	
	No. of Shares	%	No. of Shares	%
MAXGAINZ FINSERVE PVT LTD	21,00,000	20.00%	21,00,000	20.00%

f Details of Shares held by Promoters/ Promoter group at the end of the year

Equity share	As at 31-03-2025		
	No. of Shares	%	% Change during the year
Pritesh Champalal Doshi	22,500	0.21%	0.00%
Maxgainz Finserve Pvt Ltd	21,00,000	20.00%	0.00%

Equity share	As at 31-03-2024		
	No. of Shares	%	% Change during the year
Pritesh Champalal Doshi	22,500	0.21%	0.00%
Maxgainz Finserve Pvt Ltd	21,00,000	20.00%	0.00%

g The company had not issued any bonus share for consideration other than cash and no share had bought back during the period of five years immediately preceding the reporting date.

h During the year no share was reserved for issue under options and contracts/commitments for the sale of shares/ disinvestment.

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 10		
Other Equity		
Reserves & Surplus		
Securities premium reserve - at the beginning of the year	450.00	450.00
Add: Addition during the year	-	-
At the end of the year	450.00	450.00
Retained earnings - at the beginning of the year	(19.86)	(18.09)
Add: Addition during the year	2.39	(1.77)
At the end of the year	(17.47)	(19.86)
Total Reserves & Surplus	432.53	430.14
Other comprehensive income	-	-
Add: Addition during the year	-	-
At the end of the year	-	-
Total Other comprehensive income	-	-
Total Other Equity	432.53	430.14

The Description of the nature and purpose of each reserve within equity is as follows:

- a) **Securities Premium Reserve:** Securities premium reserve is credited when shares are issued at premium. It is utilised in accordance with the provisions of the Act, to issue bonus shares, to provide for premium on redemption of shares or debentures, write-off equity related expenses like underwriting costs, etc.
- b) **Retained earnings:** Retained earnings represents undistributed profits of the company

LOOKS HEALTH SERVICES LIMITED**Notes to financial statements as on 31st March 2025***(Currency: Indian Rupees in Lakhs)*

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 11		
DEFERRED TAX LIABILITIES (NET)		
The movement on the deferred tax account is as follows:		
At the start of the year	3.77	5.78
Charge/(credit) to statement of Profit and Loss	(2.24)	(2.01)
At the end of the year	1.52	3.77
MAT Credit Entitlement	-	-
Total	1.52	3.77

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 12		
Other financial Liabilities		
Audit Fees Payable	-	0.32
Total	-	0.32
Notes: - Regarding Dues to micro, small and medium enterprises, of the Financial Statements regarding dues to Dues to micro and small enterprises, Please refer Note 42		

Particulars	As at 31st March' 2025	As at 31st March' 2024
Note: 13		
Other current liabilities		
Internal Audit Fees Payable	0.03	0.05
Creditor For Expenses	0.04	-
Advance From Debtors	10.70	-
Statutory Dues Payable		
Profession Tax Payable	-	0.01
TDS Payable	-	0.25
Total	10.77	0.32

LOOKS HEALTH SERVICES LIMITED**Notes to financial statements as on 31st March 2025***(Currency: Indian Rupees in Lakhs)*

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 14		
Income from Operation		
Sale of Medicine	-	-
Sales of Services - Export	39.47	-
Total	39.47	-

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 15		
Other Income		
Balance Written Back	-	0.06
Interest income:		
On Income Tax Refund	0.10	0.18
On Loans & Advances	38.95	45.52
Total	39.05	45.76

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 16		
Employee Benefit Expenses		
Salary & Other Allowances	32.76	26.23
Directors' remuneration	0.90	0.90
Total	33.66	27.13

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 17		
Finance Cost		
Bank Charges	0.00	0.00
Total	0.00	0.00

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 2		
Depreciation	14.17	14.17
Total	14.17	14.17

Particulars	Year Ended on 31st March' 2025	Year Ended on 31st March' 2024
Note: 18		
Other Expenses -		
Advertisement	0.30	0.33
Audit Fees	3.09	0.35
Professional Fees	14.08	0.10
Share Connectivity Exp	2.05	2.31
Annual Listing Fees	3.25	3.25
Conveyance Fees	0.07	0.03
Office Expenses	0.09	0.10
Roc Filing & other Appeal Filing Exp.	0.05	0.05
Late Return Filing Fees - PT / GST	-	-
Cloud Storage Expenses	0.04	0.03
Interest On Late Payment - TDS	0.73	0.00
Interest On Late Payment - BSE	0.04	-
Interest On Late Payment - MVT	1.86	-
MVAT Tax Paid	1.89	-
Profession Tax Paid	0.01	-
Printing & Stationery	0.05	0.01
Balance W/off	0.00	0.00
Software Expenses	0.09	0.15
Staff Welfare Expenses	0.07	0.07
Web Portal & Domain Charges	0.06	0.05
Total	27.80	6.83

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
(Currency: Indian Rupees in Lakhs)

Note No

19 Contingent liability, to the extent not provided for

Particulars	As at 31 March 2025	As at 31 March 2024
VAT Demand for FY 2013-2014 (Amount paid against demand under Appeal)	3.48 (3.48)	3.48 (3.48)
Service Tax Demand for FY 2014-2015 (Amount paid against demand under Appeal)	8.64 (0.87)	8.64 (0.87)

Note:

- There are no other contingent liabilities as at the balance sheet date.
- The company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Board does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.
- Capital commitment for value of contracts yet to be executed Rs. Nil (P.Y. Nil)

20 Employee benefit obligations

Since Company does not have minimum no. of employees required to mandatorily attract Employee Benefit regulations, Company has not provided for the same.

21 Segmental Information

The Company operates in a single reportable segment i.e. medical services, which has similar risks and returns for the purpose of IND-AS - 108 on 'Segment Reporting'. The Company operates in single geographical segment, i.e. domestic.

22 Financial Instruments

Financial instrument by category

The carrying value and fair value of financial instrument by categories as of 31 March 2025 were as follows

Particulars	At amortised cost	At fair value through P&L	At fair value through OCI	Total Carrying value	Total fair value
Assets:					
Cash and cash equivalents	30.61	-	-	30.61	30.61
Loans	-	-	-	-	-
Other financial assets	-	-	-	-	-
Loans	-	-	-	-	-
Investments	-	-	-	-	-
Total	70.08	-	-	70.08	70.08
Liabilities:					
Short term borrowing	-	-	-	-	-
Trade and other payables	-	-	-	-	-
Other financial liabilities	-	-	-	-	-
Total	-	-	-	-	-

The carrying value and fair value of financial instrument by categories as of March 31, 2024 were as follows

Particulars	At amortised cost	At fair value through P&L	At fair value through OCI	Total Carrying value	Total fair value
Assets:					
Cash and cash equivalents	8.15	-	-	8.15	8.15
Loans	784.00	-	-	784.00	784.00
Other financial assets	-	-	-	-	-
Total	792.15	-	-	792.15	792.15
Liabilities:					
Short term borrowing	-	-	-	-	-
Trade and other payables	-	-	-	-	-
Other financial liabilities	0.32	-	-	0.32	0.32
Total	0.32	-	-	0.32	0.32

- (1) Assets that are not financial assets, in the opinion of the management are not included.
- (2) Other liabilities that are not financial liabilities, in the opinion of the management are not included.
- (3) In the opinion of the management, based on the details available with the company, all the financial assets and liabilities are tested for valuation, to identify their fair value, as prescribed in Indian Accounting Standards, and are measured at fair value, to the extent possible. The assets/ liabilities, which are not possible to be measured at fair value, in the opinion of the management, are presented in the financial statements at their book value, without any adjustment towards fair valuation.

23 Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The following table presents fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of 31 March 2025:

Particulars	As at 31 March 2025	Fair value measurement at end of the reporting year using		
		Level 1	Level 2	Level 3
Assets /Liabilities measured at fair value				
Financial Assets:				
Non current investments	-	-	-	-
Forward contract receivable	-	-	-	-
Financial Liabilities:				
Forward contract payable	-	-	-	-
Security deposits	-	-	-	-

The following table presents fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of 31 March 2024:

Particulars	As at 31 March 2024	Fair value measurement at end of the reporting year using		
		Level 1	Level 2	Level 3
Assets /Liabilities measured at fair value				
Financial Assets:				
Non current investments	-	-	-	-
Forward contract receivable	-	-	-	-
Financial Liabilities:				
Forward contract payable	-	-	-	-
Security deposits	-	-	-	-

There have been no transfers among Level 1, Level 2 and Level 3 during the period.

The management assessed that cash and cash equivalents, Trade receivable and other financial asset, trade payables and other financial liabilities approximate their carrying amount largely due to short term maturity of these instruments.

24 Financial risk management objectives and policies

The risk management policies of the Company are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

The Management has overall responsibility for the establishment and oversight of the Company's risk management framework.

In performing its operating, investing and financing activities, the Company is exposed to the Credit risk, Liquidity risk and Market risk.

25 Carrying amount of financial assets and liabilities:

The following table summaries the carrying amount of financial assets and liabilities recorded at the end of the period by categories:

Particulars	As at 31 March 2025	As at 31 March 2024
Financial assets -		
Cash and cash equivalent	30.61	8.15
Loans	-	784.00
Other financial assets	-	-
At end of the year	30.61	792.15
Financial liabilities -		
Borrowings	-	-
Trade payables	-	-
Other financial liabilities	-	0.32
At end of the year	-	0.32

26 Credit risk on financial assets

Financial assets that are potentially subject to concentrations of credit risk and failures by counterparties to discharge their obligations in full or in a timely manner consist principally of cash balances with banks, cash equivalents and receivables, and other financial assets. The maximum exposure to credit risk is: the total of the fair value of the financial instruments and the full amount of any loan payable commitment at the end of the reporting year. Credit risk on cash balances with banks is limited because the counterparties are entities with acceptable credit ratings. Credit risk on other financial assets is limited because the other parties are entities with acceptable credit ratings.

Cash and cash equivalents balances generally represent short term deposits with a less than 180-day maturity.

As part of the process of setting customer credit limits, different credit terms are used. The average credit period generally granted to trade receivable customers is about 90-360 days. But some customers take a longer period to settle the amounts.

27 Exposure to credit risk

Financial asset for which loss allowance is measured using expected credit loss model

Particulars	As at 31 March 25	As at 31 March 24
Financial assets -		
Cash and cash equivalent	30.61	8.15
Loans	-	784.00
Other financial assets	-	-
At end of the year	70.08	792.15

With the applicability of Ind AS 109, the recognition and measurement of impairment of financial assets is based on credit loss assessment by expected credit loss (ECL) model. The ECL assessment involve significant management judgement. The Company's impairment allowance is derived from estimates including the historical default and loss ratios. Management exercises judgement in determining the quantum of loss based on a range of factors, like staging criteria, calculation of probability of default / loss and consideration of probability weighted scenarios and forward looking macroeconomic factors.

The board acknowledges and understands that these factors, since there is a large increase in the data inputs required by the ECL model, which increases the risk of completeness and accuracy of the data that has been used to create assumptions in the model. Based on the internal management analysis, as per Board Opinion, there is no requirement of provision for expected credit loss in several financial assets including the trade receivables and other receivables of the Company and all are on fair value, based on the assessment and judgement made by the board of the company.

In the opinion of management, trade receivable, Financial assets, Cash and cash equivalent, Balance with Bank, Loans and other financial assets have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
(Currency: Indian Rupees in Lakhs)

28 Market risk -

Market risk is the risk that changes in market prices – such as foreign exchange rates and interest rates – will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables and long term debt. We are exposed to market risk primarily related to foreign exchange rate risk and interest rate risk. Thus, our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

29 Foreign currency risk

As of the reporting date, the Company had minimal exposure to foreign currency risk.

During the financial year ended 31/03/2025, the Company entered into a single foreign currency transaction, invoice denominated in USD, which was recorded on March 31, 2025, the last day of the financial year.

As the transaction was recognized at the prevailing exchange rate on the reporting date, no foreign exchange gain or loss was recorded in the financial statements for the year ended 31/03/2025. The foreign currency-denominated receivable/payable will be subject to exchange rate fluctuations in the subsequent reporting period until it is settled. The Company continues to monitor its foreign currency exposures and will assess the need for hedging strategies should exposure levels increase in the future. The functional currency of the Company is Indian Rupee.

30 Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing financial instruments because of fluctuations in the interest rates. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing financial instruments will fluctuate because of fluctuations in the interest rates.

Company has interest rate risk exposure mainly from changes in rate of interest on borrowing & on deposit with bank. The interest rate are disclosed in the respective notes to the financial statements of the Company.

The following table analyse the breakdown of the financial assets and liabilities by type of interest rate:

Particulars	As at 31 March 25 (Rs.)	As at 31 March 24 (Rs.)
Financial assets		
Interest bearing - Fixed interest rate		
- Loans	-	784.00
Interest bearing - Floating interest rate	-	-
Financial Liabilities		
Interest bearing - Fixed interest rate	-	-
Interest bearing - Floating interest rate		

31 Fair value sensitivity analysis for fixed-rate instruments

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

32 Cash flow sensitivity analysis for variable-rate instruments -

The company does not have any financial assets or financial liabilities bearing floating interest rates. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

33 Liquidity risk -

Liquidity risk is the risk that the Company may not be able to meet its present and future cash and collateral obligations without incurring unacceptable losses. The Company's objective is to, at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Company closely monitors its liquidity position and deploys a robust cash management system. It maintains adequate sources of financing including debt and overdraft from banks at an optimised cost.

The Company maximum exposure to credit risk for the components of the balance sheet at 31 March 2024 and 31 March 2023 is the carrying amounts. The liquidity risk is managed on the basis of expected maturity dates of the financial liabilities. The average credit period taken to settle trade payables is about 90 days. The other payables are with short-term durations. The carrying amounts are assumed to be a reasonable approximation of fair value. The following table analysis financial liabilities by remaining contractual maturities:

Particulars	On Demand	12 months or less	1 to 5 years	> 5 years	Total
Year ended 31 March 2025					
Other financial liabilities	-	-	-	-	-
Trade and other payables	-	-	-	-	-
Total	-	-	-	-	-
Year ended 31 March 2024					
Other financial liabilities	-	0.32	-	-	0.32
Trade and other payables	-	-	-	-	-
Total	-	0.32	-	-	0.32

At present, the Company does expects to repay all liabilities at their contractual maturity. In order to meet such cash commitments, the operating activity is expected to generate sufficient cash inflows.

34 Capital management -

For the purpose of the Company's capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders of the parent. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company's policy is to keep optimum gearing ratio. The Company includes within net debt, interest bearing loans and borrowings, trade and other payables, less cash and cash equivalents, excluding discontinued operations.

Particulars		As at 31 March 25	As at 31 March 24
Borrowings			
Trade & Other payables		-	-
Other financial liabilities		-	0.32
Less: cash and cash equivalents		(30.61)	(8.15)
Net debt	(a)	(30.61)	(7.84)
Total equity			
Total member's capital	(b)	1,482.53	1,480.14
Gearing ratio (%)	(a/b)	-2.06%	-0.53%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing in the current period.

No changes were made in the objectives, policies or processes for managing capital during the years ended 31 March 2025 and 31 March 2024.

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
(Currency: Indian Rupees in Lakhs)

35 Income tax

The major components of income tax expense for the years are:

Particulars	As at 31 March 2025	As at 31 March 2024
Current income tax:		
Current income tax charge	2.74	1.42
Adjustments in respect of previous year	-	-
MAT credit entitlement	-	-
Deferred tax:		
Relating to origination and reversal of temporary differences	(2.24)	(2.01)
Income tax expense reported in the statement of profit or loss	0.50	(0.59)

A Reconciliation of income tax provision to the amount computed by applying the statutory income tax rate to the income before Income taxes is summarized as follow:

Particulars	As at 31 March 2025	As at 31 March 2024
Profit before income tax	2.89	(2.36)
Rate of Income tax	25.168%	25.17%
Tax using the Company's domestic tax rate	0.73	(0.59)
Tax effect of:		
Additional allowances for tax purpose	(1.32)	(1.56)
Expenses not allowed for tax purposes	4.22	3.57
Other Adjustments	-	-
Relating to origination and reversal of temporary differences	(2.24)	(2.01)
Adjustments in respect of previous year	-	-
Income tax expense reported in the statement of profit or loss	1.38	(0.59)

Applicable statutory tax rate for financial year 2024-25 is 25.168%.

Movement in deferred tax balances

Particulars	<u>31-03-2025</u>	<u>31-03-2024</u>
Opening balance April 1 -(Asset)/ Liabilities		
Property, plant and equipment	3.77	5.78
Deferred tax (Asset)/Liabilities- Recognised in profit or loss		
Property, plant and equipment	(2.24)	(2.01)
Closing balance March 31 -(Asset)/ Liabilities		
Property, plant and equipment	1.52	3.77

The company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income by each jurisdiction in which the relevant entity operates and the period over which deferred income tax assets will be recovered.

36 Estimates

The estimates at 1 April 2025 and at 31 March 2024 are consistent with those made for the same dates in accordance with Indian AS (after adjustments to reflect any differences in accounting policies).

- 37 Balance of Receivables and Payables, including loans , deposits & trade advances given, payable to vendors, etc, are subject to confirmation and consequent reconciliation and adjustments, if any. Further the impairment provision for trade advances given are subject to documentation of the informal updation in terms of advances. Hence, the effect thereof, on Profit/ Loss, Assets and Liabilities, if any, is not ascertainable, which may be considerable. As per the opinion of the Board, there will be no substantial impact on their reconciliation with their balance confirmations as on the reporting date.

- 38 There was no impairment loss on the fixed assets on the basis of review carried out by the management in accordance with Indian Accounting Standard (Ind AS)–36 "Impairment of Assets"

39 **Lease disclosure**

Nature of Lease Activity - Company had entered into Lease Agreement for its Goa Clinic's Premise but in FY20-21 same was surrendered.

Amount recognised in Profit and Loss during the Year -

<u>Particulars</u>	<u>As at</u> <u>31 March 2025</u>	<u>As at</u> <u>31 March 2024</u>
Short Term Leases (Surrendered during the previous year)	-	-

On adoption of Ind AS 116, the Company recognised lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of AS-17 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate. The weighted average incremental borrowing rate applied to the lease liabilities was 9%. During the Financial Year ended 31-03-2021, the underlying lease agreements have been surrendered. Hence entire liabilities were reversed by the company.

Future Min. Lease Payments due as on 31.03.2025 is as follows -

Min. Lease Payment due	Total Amt. Payable	Finance Charges	Net Present Value of Lease Liability
Within 1Yr	-	-	-
2nd Year	-	-	-
3rd Year	-	-	-
4th year	-	-	-
5th year	-	-	-
Total	-	-	-

40 **Earnings per share**

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of equity shares outstanding during the year plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

The following reflects the income and share data used in the basic and diluted EPS computations:

<u>Particulars</u>	<u>As at</u> <u>31 March 2025</u>	<u>As at</u> <u>31 March 2024</u>
Profit attributable to equity holders of the parent for basic earnings (Rs.)	2.39	(1.77)
Weighted average number of equity shares for basic and diluted earning per share	1,05,00,000	1,05,00,000
Face value per share	10	10
Basic earning per share	0.02	-0.02
Diluted earning per share	0.02	-0.02

- 41 The Company has not entered into any transactions which are termed "Specified Domestic Transaction" as per Section 92BA of the Income Tax-Act, 1961. Accordingly, it is not required to comply with certain transfer pricing regulations under Section 92 to Section 92F of the Act. "
- 42 The Company has an informal process of obtaining confirmations from the vendors to record whether they are covered under Micro, Small and Medium Enterprise Development Act 2006 as well as they have filed required memorandum with prescribed authority. Based on and to the extent of the information received by the Company from the suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) and relied upon by the auditors, the relevant particulars as at the year end are furnished below:

Dues to micro, small and medium enterprises	Rs in Lacs	
	31-Mar-25	31-Mar-24
The amounts remaining unpaid to micro and small suppliers as at the end of the year		
Principal	-	0.32
Interest	Nil	Nil
The amount of interest paid by the buyer as per the Micro Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006)	-	-
The amounts of the payments made to micro and small suppliers beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006	-	-

The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under the MSMED Act, 2006	-	-

43 The Company has carried out Impairment test on its Fixed Assets as on the date of Balance Sheet and the management is of the opinion that there is no asset for which provision of impairment is required to be made as per applicable Indian Accounting Standard.

44 Revaluation/ Fair valuation of PPE / Intangible assets/ Investment property

There was no revaluation of Property, Plant and Equipment (including Right-of-Use Assets) and intangible assets held by the company during the year. The company also does not have any Investment property during the current year as well as previous year.

45 Benami Property held under Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder

The Company do not have any benami property, where any proceeding has been initiated or pending against the company for holding any Benami property.

46 Wilful Defaulter

The Company is not declared as wilful defaulter by any bank or financial Institution or other lender.

47 Misutilisation of Bank Borrowing

The company has not taken any borrowings from banks and financial institutions during the current year as well as previous year.

48 Disclosure of transactions with struck off companies

The Company did not have any material transactions with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the financial year.

49 Compliance with approved Scheme(s) of Arrangements

No Scheme of Arrangements has been approved by/ pending with the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013 during the year as well as previous year

50 Undisclosed Income

The Company have not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

51 Compliance with number of layers of companies

The compliance of number of layers of companies, prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017, are not applicable to the company

52 Details of Crypto Currency or Virtual Currency

The Company has not traded or invested in Crypto currency or Virtual Currency during the current financial year and any of the previous financial years.

53 Security of current assets against borrowings

The Company has no borrowings from banks or financial institutions on the basis of security of current assets.

54 Utilisation of Borrowed funds and share premium:

- (A) During the year, the company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries)
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (B) During the year, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party(Ultimate Beneficiaries)
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

55 Registration of charges or satisfaction of charges with Registrar of Companies (ROC)

The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

LOOKS HEALTH SERVICES LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

56 **Related party relationships, transactions and balances**

A	Nature of relationship																						
	I Holding Company - NA																						
II	Subsidiary Company - NA																						
III	Enterprises over which Directors and their relatives exercise significant influence																						
IV	Key Management Personnel and their relatives																						
	<table> <tr><td>1</td><td>Pritesh Champalal Doshi (Managing Director - Appointed On 24/12/2011)</td></tr> <tr><td>2</td><td>Sejal Hitesh Jain (Independent Director - Appointed On 01/04/2021)</td></tr> <tr><td>3</td><td>Krishna Mukesh Sangani (Independent Director - Appointed on 10/08/2024 & Resigned on 30/09/2024)</td></tr> <tr><td>4</td><td>Devendra Bhogilal Sanghvi (Independent Director - Appointed on 01/09/2018 & Resigned on 10/08/2024)</td></tr> <tr><td>5</td><td>Bhavin Mahendrakumar Hirapar (Director Appointed on 05/09/2024)</td></tr> <tr><td>6</td><td>Dhruv Pravinbhai Rajgor (Director Appointed on 05/09/2024)</td></tr> <tr><td>7</td><td>Monika Joshi (Whole Time Director Appinted on 05/09/2024)</td></tr> <tr><td>8</td><td>Mihir Ganappa (Director Appointed on 05/09/2024)</td></tr> <tr><td>9</td><td>CS Kanchan Kaku (Company Secretary- from 01.04.2021 and Resigned On 17/02/2025)</td></tr> <tr><td>10</td><td>CS Vandanaben Sheladiya (Company Secretary- Appointed On 24/04/2025)</td></tr> <tr><td>11</td><td>Milinand Gavas (CFO - Appointed On 01/04/2021)</td></tr> </table>	1	Pritesh Champalal Doshi (Managing Director - Appointed On 24/12/2011)	2	Sejal Hitesh Jain (Independent Director - Appointed On 01/04/2021)	3	Krishna Mukesh Sangani (Independent Director - Appointed on 10/08/2024 & Resigned on 30/09/2024)	4	Devendra Bhogilal Sanghvi (Independent Director - Appointed on 01/09/2018 & Resigned on 10/08/2024)	5	Bhavin Mahendrakumar Hirapar (Director Appointed on 05/09/2024)	6	Dhruv Pravinbhai Rajgor (Director Appointed on 05/09/2024)	7	Monika Joshi (Whole Time Director Appinted on 05/09/2024)	8	Mihir Ganappa (Director Appointed on 05/09/2024)	9	CS Kanchan Kaku (Company Secretary- from 01.04.2021 and Resigned On 17/02/2025)	10	CS Vandanaben Sheladiya (Company Secretary- Appointed On 24/04/2025)	11	Milinand Gavas (CFO - Appointed On 01/04/2021)
1	Pritesh Champalal Doshi (Managing Director - Appointed On 24/12/2011)																						
2	Sejal Hitesh Jain (Independent Director - Appointed On 01/04/2021)																						
3	Krishna Mukesh Sangani (Independent Director - Appointed on 10/08/2024 & Resigned on 30/09/2024)																						
4	Devendra Bhogilal Sanghvi (Independent Director - Appointed on 01/09/2018 & Resigned on 10/08/2024)																						
5	Bhavin Mahendrakumar Hirapar (Director Appointed on 05/09/2024)																						
6	Dhruv Pravinbhai Rajgor (Director Appointed on 05/09/2024)																						
7	Monika Joshi (Whole Time Director Appinted on 05/09/2024)																						
8	Mihir Ganappa (Director Appointed on 05/09/2024)																						
9	CS Kanchan Kaku (Company Secretary- from 01.04.2021 and Resigned On 17/02/2025)																						
10	CS Vandanaben Sheladiya (Company Secretary- Appointed On 24/04/2025)																						
11	Milinand Gavas (CFO - Appointed On 01/04/2021)																						
V	Fellow Associates - NA																						

Notes :

- The related party relationship have been determined on the basis of the requirement of the Indian Accounting Standard (Ind AS) - 24 'Related Party Disclosures and the same have been relied upon by the auditors.
- The relationships as mentioned above pertain to those related parties with whom transactions have taken place during the current year/previous year, except where control exists, in which case the relationships have been mentioned irrespective of transactions with the related party.

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2024
(Currency: Indian Rupees in Lakhs)

Related Party Disclosures: (Continued)

B. Transaction with related parties for the Year ended -

Nature of transactions	Enterprises on which key management personnel (KMP's) have significant influence		KMP	
	Year Ended 31st March 2025	Year Ended 31st March 2024	Year Ended 31st March 2025	Year Ended 31st March 2024
<u>Remuneration Paid</u>				
PRITESH DOSHI	-	-	0.90	0.90
CS KANCHAN KAKU	-	-	7.56	7.63
MILINATH GAVS	-	-	2.40	2.40
<u>Reimbursement of Expenses</u>				
PRITESH DOSHI	-	-	-	-
<u>Deposit Loans and Advance taken</u>				
PRITESH DOSHI	-	-	-	-
<u>Deposit Loans and Advance repaid back</u>				
PRITESH DOSHI	-	-	-	-

C. Balances Outstanding at the year end with the Related Parties:

Nature of transactions	Enterprises on which key management personnel (KMP's) have significant influence		KMP & their Relatives	
	Year Ended 31st March 2025	Year Ended 31st March 2024	Year Ended 31st March 2025	Year Ended 31st March 2024
Unsecured Loan Taken/ Business Advance Payable				
	-	-	-	-
	-	-	-	-
Unsecured Loan Given/ Business Advance Receivable				
	-	-	-	-
	-	-	-	-
	-	-	-	-

Terms and conditions of transactions with related parties

- All Related Party Transactions entered during the year were in ordinary course of the business and on arm's length basis.
- Outstanding balances at the year-end are unsecured and settlement occurs in cash.
- There have been no guarantees provided or received for any related party receivables or payables.
- For the current year, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (Previous Year: Rs. Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
(Currency: Indian Rupees in Lakhs)

57 Title deeds of Immovable Properties not held in name of the Company

The Company do not have any immovable properties where title deeds are not held in the name of the company.

58 Trade Payables ageing schedule

Particulars	Outstanding for following periods from due date of payment					
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
As on 31.03.2025						
(i) MSME*	-	-	-	-	-	-
(ii) Others	-	-	-	-	-	-
(iii) Disputed dues — MSME*	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
Total	-	-	-	-	-	-
As on 31.03.2024						
(i) MSME*	-	-	-	-	-	-
(ii) Others	-	-	-	-	-	-
(iii) Disputed dues — MSME*	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
Total	-	-	-	-	-	-

*MSME as per the Micro, Small and Medium Enterprises Development Act, 2006, as per information available with the Company

58 Loans and Advances to promoters, directors, KMPs and the related parties (as defined under the Companies Act, 2013)

The company has granted following loans or advances in the nature of loans which are granted to promoters, directors, KMPs and the related parties (as defined under the Companies Act, 2013), either severally or jointly with any other person that are (a) repayable on demand; or (b) without specifying any terms or period of repayment.

Type of Borrower, that are (a) repayable on demand; or (b) without specifying any terms or period of repayment.	Amount of loan or advance in the nature of loan outstanding		Percentage to the total Loans and Advances in the nature of loans	
	As on		As on	
	31.03.2025	31.03.2024	31.03.2025	31.03.2024
Promoters/ Directors/ KMPs:	-	-	0	0.00%
Related Parties:	-	-	0	0.00%
Total to promoters, directors, KMPs and the related parties	-	-	0	0.00%
Total to Other Loans given by the Company	-	784.00	-	100.00%
Grand Total	-	784.00	0.00%	100.00%

59 The details of loan granted by the company during the Financial Year 2024-25 are as follows:

Loan Provided	Sub./ JV/ Associate	Others
A. Aggregate amount granted/ provided during the year	-	-
B. Balance outstanding as at balance sheet date in respect of above cases	-	-

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

(Currency: Indian Rupees in Lakhs)

60 Analytical Ratios

(Currency: Indian Rupees in lakhs)

Sr. No.	Ratio Analysis	Numerator	Denominator	31.03.2025	31.03.2024	% Variance	Reason for variance (above 25%)
1	Current Ratio	Current Assets	Current Liabilities	7.33	32.36	-77.34%	Due to increase in current liabilities (On Account of Provision of Tax as Company earned Net Profit) result in Decrease in Current Ratio 31.03.2025
2	Debt Equity Ratio	Total Debts	Total Shareholders Equity	-	-	N.A.	--
3	Debt Service Coverage Ratio	Earning for Debt Service	Debt Service	N.A.	N.A.	N.A.	--
4	Return on Equity Ratio	Net Profit for the period	Average Shareholders Equity	0.16%	-0.12%	-235.29%	Due to company has provided Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25
5	Inventory Turnover Ratio	Cost of Goods sold	Average Inventory	N.A.	N.A.	N.A.	--
6	Trade Receivables Turnover Ratio	Revenue from operations	Average Trade Receivables	2.00	N.A.	N.A.	Company has start providing health Care services during FY 2024-25
7	Trade Payables Turnover Ratio	Total Purchases	Average Trade Payables	N.A.	N.A.	N.A.	Due to non purchase in FY 2024-25
8	Net Capital Turnover Ratio	Revenue from operations	Average Working Capital	0.90	-	N.A.	Due to No sale Income during the Current Year
9	Net Profit Ratio	Net Profit After Tax	Revenue from operations	6.05%	N.A.	N.A.	Due to company has provided Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25
10	Return on Capital employed	EBIT	Capital Employed	0.20%	-0.16%	-221.88%	Due to company has provided Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25
11	Return on Investment	Net Profit After Tax	Average Total Assets	0.16%	-0.12%	-234.45%	Due to company has provided Health Services in FY 2024-25 and because of that overall Improve in Net Profit for FY 2024-25

Note:

1. Total Debt = Long term Borrowings (including current maturities of Long term Borrowings), lease liabilities (current and non- current), short term borrowings and Interest accrued on Debts
2. Earning for Debt Service = Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets etc.
3. Debt service = Interest & Lease Payments + Principal Repayments
4. Avg. Shareholder's Equity = Average of Opening Total Equity and Closing Total Equity excluding revaluation reserve

5. Average Inventory = Average of Opening Inventory and Closing Inventory
6. Average Trade Receivable = Average of Opening Trade Receivables and Closing Trade Receivables
7. Average Trade Payables = Average of Opening Trade Payables and Closing Trade Payables
8. Working capital shall be calculated as current assets minus current liabilities
9. EBIT = Earning before interest and taxes
10. Capital Employed = Tangible Net Worth (excluding revaluation reserve) + Total Debt + Deferred Tax Liability
11. Average Total Assets = Average of Opening Total Assets and Closing Total Assets excluding revaluation impact

LOOKS HEALTH SERVICES LIMITED
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
(Currency: Indian Rupees in Lakhs)

61 These financial statements are presented in Indian Rupees (INR), which is also its functional currency and all values are rounded to the nearest Lakhs, except when otherwise indicated. The amounts which are less than Rs. 0.01 Lakhs are shown as Rs 0.00 Lakhs.

62 Previous year's figures have been regrouped or reclassified wherever necessary.

As per our Report of even date

For KPSJ & Associates LLP

Chartered Accountants

(Firm Reg. No. 124845W/W100209)

-

-

Prakashchandra Parakh

(Partner)

M.No. 039946

UDIN: 25039946BMIFAO6391

Place : Ahmedabad

Date : 26/05/2025

For and on behalf of the Board

Looks Health Services Limited

Pritesh Champalal Doshi

(Managing Director)

DIN: 05155318

Monika Joshi

(WTD)

DIN: 10652494

Vandanaben Ajeshkumar Sheladiya

Milnath Gavas

(Company Secretary)

ICSI Member No: A45323

Place : Ahmedabad

(CFO)